Target variant reference set for estimating target variants
By generating a target variant reference set and performing genotype estimation, the problem of inaccurate variant detection in difficult-to-detect genomic regions by existing sequencing systems has been solved, achieving accurate genotype detection of genomic regions such as RFC1 and CYP2D6, and improving computational efficiency and accuracy.
Patent Information
- Application Number
- CN202380031207.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-09-29
- Filing Date
- 2023-09-27
- Publication Date
- 2024-11-15
AI Technical Summary
Existing sequencing systems cannot accurately detect variants in genomic regions that are difficult to detect, such as those with variable number tandem repeat (VNTR) amplification, short tandem repeat (STR) amplification, structural variants, or other types of variant regions, leading to inaccurate genotype detection, especially in genomic regions such as the RFC1 gene and the CYP2D6 gene.
A target variant reference set is generated. By adding the target variant position to the initial reference set, the target variant reference set is used to infer genotype detection. This includes phasing alleles of the genomic sample to identify the presence or absence of the target variant, thereby improving the accuracy of genotype detection.
It improves the accuracy of genotype detection for repetitive sequence amplification and other variants, reduces the consumption of computing resources, improves computer processing efficiency, and can accurately identify variants of genomic regions that are difficult to detect.
Smart Images

Figure CN118974830A_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims the benefit of and priority to U.S. Provisional Application No. 63 / 377,682, filed on September 29, 2022, entitled “ATARGET-VARIANT-REFERENCE PANEL FOR IMPUTING TARGET VARIANTS”, which is hereby incorporated by reference in its entirety. Background Art
[0003] In recent years, biotechnology companies and research institutions have improved the hardware and software for nucleotide sequencing and determining the base calls of genome samples. For example, some existing sequencers and sequencing data analysis software (collectively referred to as "existing sequencing systems") predict individual nucleotides within a sequence by using conventional Sanger sequencing or sequencing by synthesis (SBS) methods. When using SBS, existing sequencing systems can monitor thousands of oligonucleotides synthesized in parallel from a template to predict the base calls of the nucleotide reads of the culture based on images of fluorescently labeled bases incorporated into the oligonucleotides. After capturing such images, some existing sequencing systems determine the base calls of the nucleotide reads corresponding to the oligonucleotides, and send the base call data to a computing device with sequencing data analysis software. By using sequencing data analysis software, existing sequencing systems compare nucleotide reads with reference genomes. Based on the differences between the compared nucleotide reads and the reference genome, existing systems can further utilize variant detectors to identify variants of genome samples, such as single nucleotide polymorphisms (SNPs), repeat amplification variants, or insertions or deletions (indels).
[0004] Despite these advances, existing sequencing systems often determine inaccurate variant calls for difficult-to-detect genomic regions, such as regions with variable number tandem repeats (VNTR) amplification, short tandem repeats (STR) amplification, structural variants, or other types of variants. For specific difficult-to-detect genomic regions of genomic samples, existing sequencing systems typically use reference groups and genotype inference models to infer nucleobase calls and phase haplotypes based on variants detected in genomic samples. For example, existing sequencing systems often use various types of hidden Markov models (HMMs) customized for inferring genotypes, such as by using genotype likelihood inference and phasing methods (GLIMPSE) or IMPUTE to infer nucleobase calls for specific genomic regions. Based on variants shared between haplotypes of reference groups and nucleotide reads of genomic samples, genotype inference models can infer variants of difficult-to-detect genomic regions of genomic samples with different accuracies.
[0005] Depending on the gene or other genomic region, variant detection of difficult-to-detect genomic regions can be insignificant or critical. Because existing sequencing systems typically use reference groups that are not sufficient to capture or mark variations in repeat expansion variants (e.g., VNTR or STR) or specific pathogenic variants, incorrect variant detection may have serious consequences. For example, variant detection that identifies a specific repeat expansion variant in the replication factor C subunit 1 (RFC1) gene can correctly or incorrectly identify the genetic indication of the phenotype on the cerebellar ataxia, neuropathy, vestibular reflex loss syndrome (CANVAS) spectrum. For example, the biallelic intron AAGGG repeat expansion in the RFC1 gene makes such variant detection particularly challenging. As another example, variant detection that correctly or incorrectly identifies a variant of the cytochrome P450 family 2 subfamily D member 6 (CYP2D6) gene can lead to the correct identification of the genetic indication of neuroleptic malignant syndrome or completely skip the genetic indication. Therefore, while variant calling of such pathogenic variants in genes can be critical, suitable reference panels with sufficient variation to support accurate variant calling are often lacking.
[0006] Although accurately determining variant calls for repeat expansions and pathogenic variants is important, existing sequencing systems often fail to generate variant calls or generate inaccurate variant calls due to poor quality nucleotide read data, poor nucleotide read alignment, or inadequate reference sets. In fact, many existing sequencing systems do not generate genotype calls or generate inaccurate genotype calls because (i) the nucleotide reads of the target genomic regions corresponding to the target variants provide insufficient coverage, (ii) the alignment model cannot accurately map the nucleotide reads of such genomic regions to the reference genome, or (iii) the existing reference set contains insufficient data to support accurate inference.
[0007] To illustrate the technical issues of (i) and (ii), some existing sequencing systems align nucleotide reads corresponding to repeat sequence expansions with target genomic regions to leave read coverage holes only in the middle of the target genomic regions. Because target genomic regions of repeat sequence expansions or pathogenic variants can exhibit such read coverage holes, existing sequencing systems do not generate genotype calls or generate inaccurate genotype calls. In fact, in the absence of direct evidence of nucleotide reads from genomic regions corresponding to repeat sequence expansions or a reference group with sufficient data for such repeat sequence expansions, existing sequencing systems cannot accurately genotype repeat sequence expansions (such as repeat sequence expansions in RFC1 and CYP21A2) or other important pathogenic variants.
[0008] These problems and challenges, along with additional problems and challenges, exist with existing sequencing systems. Summary of the invention
[0009] The present disclosure describes one or more embodiments of systems, methods, and non-transient computer-readable storage media that solve one or more of the above problems or provide other advantages over the prior art. For example, the disclosed system may generate a target variant reference group including a target variant position with a target variant indication, or use the target variant reference group to infer the genotype detection of the corresponding target variant. More specifically, in one or more embodiments, the disclosed system generates an initial reference group of multiple phased genomic samples including different haplotypes. The disclosed system also adds the target variant position to the initial reference group to indicate the presence or absence of the target variant, thereby creating a target variant reference group including a target variant position with a target variant indication. Additionally or alternatively, the disclosed system may be based on (i) the haplotype represented in the target variant reference group and (ii) the comparison of the nucleotide reads corresponding to the target genome sample, and the target variant reference group is used to infer the genotype detection indicating the presence or absence of the target variant in the target genome sample.
[0010] Additional features and advantages of one or more embodiments of the present disclosure will be outlined in the description which follows, and in part will be obvious from the description, or may be learned by practice of such exemplary embodiments. BRIEF DESCRIPTION OF THE DRAWINGS
[0011] DETAILED DESCRIPTION One or more embodiments are briefly described below through use of the accompanying drawings, providing additional specificity and detail.
[0012] Figure 1 A schematic diagram of a computing system in which a custom genotype imputation system may operate is shown according to one or more embodiments.
[0013] Figure 2A A customized genotype imputation system for generating a reference panel of target variants according to one or more embodiments is shown.
[0014] Figure 2B A custom genotype imputation system that utilizes a target variant reference panel to impute genotype calls according to one or more embodiments is shown.
[0015] Figure 3 Nucleotide reads of a genomic sample that are not aligned to a genomic region comprising a repetitive sequence expansion according to one or more embodiments are shown.
[0016] Figure 4 Shown are clustering patterns of genomic samples including target variants according to one or more embodiments.
[0017] Figure 5A customized genotype imputation system for generating a target variant reference set including target variant positions according to one or more embodiments is shown.
[0018] Figure 6 An exemplary output file including a reference set of target variants according to one or more embodiments is shown.
[0019] Figure 7 Shown is a graph depicting non-reference genotype concordance rates for a customized genotype imputation system using a target variant-specific target variant reference set relative to allele frequencies according to one or more embodiments.
[0020] Figure 8 A customized genotype imputation system that utilizes a target variant reference set to impute genotype calls of target variants within a genomic sample is shown in accordance with one or more embodiments.
[0021] Fig. 9 A graphical user interface for providing information about imputed genotype calls for target variants is shown according to one or more embodiments.
[0022] Fig.10 A flow chart showing a series of actions for generating a reference set of target variants according to one or more embodiments is shown.
[0023] Fig.11 A flow chart showing a series of actions for inferring genotype calls using a reference set of target variants according to one or more embodiments.
[0024] Fig.12 A block diagram of an exemplary computing device for implementing one or more embodiments of the present disclosure is shown. DETAILED DESCRIPTION
[0025] The present disclosure describes one or more embodiments of a custom genotype imputation system, which generates a target variant reference group including a target variant position indicated by a target variant, or uses a target variant reference group to impute the genotype detection of a corresponding target variant. To illustrate, in one or more embodiments, a custom genotype imputation system creates an initial reference group of a genomic sample including a genetic diversity haplotype. The custom genotype imputation system also adds the target variant position to the initial reference group, and phases the alleles of the genomic sample to determine the presence or absence of the target variant in the corresponding alleles present in the maternal haplotype and the paternal haplotype. By adding such target variant positions, the custom genotype imputation system generates a target variant reference group including a target variant indication within the target variant position of the phased allele of the genomic sample. After generating or accessing such a target variant reference group, in one or more embodiments, the custom genotype imputation system uses the target variant reference group to determine the genotype detection indicating the presence or absence of the target variant in the target genomic sample.
[0026] As mentioned, in one or more embodiments, the customized genotype imputation system generates a target variant reference group. In order to generate the target variant reference group, in one or more embodiments, the customized genotype imputation system generates an initial reference group including a genomic sample with a genetic diversity haplotype. For illustration, in one or more embodiments, the customized genotype imputation system generates an initial reference group including genomic samples from various populations, ancestors, continents and / or countries. In some embodiments, the haplotype in the initial reference group includes one or more marker variants, such as single nucleotide polymers (SNPs) or small insertions and / or deletions.
[0027] Based on the initial reference group, in some specific implementations, the custom genotype imputation system generates a target variant reference group by adding the target variant position to the initial reference group. For example, in some embodiments, the custom genotype imputation system adds a data field as a placeholder for the indication of the target variant in the allele of the various haplotypes represented in the initial reference group. In one or more embodiments, the custom genotype imputation system inserts the target variant indication into such data field (or another target variant position) to indicate whether a given genomic sample includes a target variant. Compared to conventional reference groups that do not include such target variant positions, the custom genotype imputation system can use the target variant position of the target variant reference group to more accurately identify the target variant.
[0028] In addition to adding the target variant position, in some cases, the custom genotype inference system is also based on the SNP or other marker variants shown by the alleles of the various haplotypes to phase the alleles of the genome sample represented by the target variant reference group. To illustrate, in some embodiments, the custom genotype inference system utilizes a haplotype phasing model to phase the alleles of the genome sample based on known haplotypes and other inheritance patterns. More specifically, in one or more embodiments, the custom genotype inference system (i) identifies one or more genomic coordinates corresponding to the target variant, and (ii) phases the alleles from the haplotype corresponding to those genomic coordinates based on the marker variants shown by the alleles. By using the indication in the target variant position to phase the alleles of the genome sample, the custom genotype inference system may include the target variant indication of the target variant of the phased alleles of the various haplotypes in the target variant reference group. As explained below, the custom genotype inference system can utilize a variety of other phasing models to phase the alleles of the genome sample represented by the target variant reference group.
[0029] In addition or in lieu of generating a target variant reference group, in one or more embodiments, a custom genotype imputation system utilizes a target variant reference group to impute one or more genotype calls of a target variant of a target genome sample. To illustrate, in one or more embodiments, a custom genotype imputation system receives and / or identifies nucleotide reads corresponding to a target genome sample. The custom genotype imputation system also accesses a target variant reference group, which includes a target variant indication within a target variant position of a phased allele of a genome sample of different haplotypes. In some embodiments, based on comparing the alleles of a haplotype represented by a target variant reference group with the nucleotide reads corresponding to a target genome sample, a custom genotype imputation system imputes the genotype calls of a target variant within a target genome sample.
[0030] For example, in one or more embodiments, the sequencing device receives a nucleotide sample slide (e.g., a flow cell) comprising oligonucleotides extracted from a target genome sample and determines nucleotide reads corresponding to the oligonucleotides of the target genome sample. In addition, or in an alternative, the custom genotype imputation system may receive data representing nucleotide reads of the target genome sample. In some cases, the custom genotype imputation system receives nucleotide reads of the target genome sample from a third-party sequencing system.
[0031] As mentioned, in one or more embodiments, the custom genotype imputation system compares the reads of the target genome sample with the alleles of the genome sample included in the target variant reference group. To illustrate, the custom genotype imputation system can identify marker variants around one or more genomic coordinates corresponding to the target variant in the target sample. The custom genotype imputation system also compares the marker variants indicated by the nucleotide reads of the target genome sample with the corresponding marker variants in the alleles of the haplotype in the target variant reference group. In some cases, the custom genotype imputation system phases the nucleotide reads of the target genome sample to identify the corresponding alleles in the maternal haplotype and the paternal haplotype in the target variant reference group.
[0032] Based on comparing the alleles of the haplotype represented by the target variant reference group with the nucleotide reads corresponding to the target genome sample, the customized genotype inference system generates a prediction of whether the target genome sample carries the target variant. To illustrate, in some cases, the customized genotype inference system determines the phased genotype detection indicating the presence or absence of the target variant at the allele corresponding to the maternal haplotype or the paternal haplotype. Therefore, the customized genotype inference system can determine whether the target genome sample is a carrier of the target variant at a specific allele, a case of the target variant at two alleles, or is not affected by the target variant at any allele. Therefore, in one or more embodiments, the customized genotype inference system can generate and provide a notification or a graphic indicating the phased genotype detection in a graphical user interface via a computing device.
[0033] As described above, the customized genotype inference system provides several technical advantages and beneficial effects that are superior to existing sequencing systems and methods. For example, the customized genotype inference system improves the accuracy of the genotype detection of the target variant. By generating or utilizing a target variant reference group to infer the genotype detection of the target variant corresponding to the haplotype of the genomic sample, the customized genotype inference system improves the accuracy of the inference of the target variant, particularly the accuracy of the inference of the difficult-to-detect genomic regions that exhibit repeat sequence amplification or other variant types. To illustrate, by utilizing a target variant reference group including a target variant position, a customized genotype inference system can generate accurate and phased genotype detection of the target variant in the genomic region of the reference genome that the nucleotide read is difficult to compare with, and the genomic region includes a genomic region where many existing sequencing systems cannot generate any genotype detection or cannot generate accurate genotype detection. For example, a customized genotype imputation system can generate accurate genotype calls for repeat sequence expansions in the RFC1 gene, the CYP2D6 gene, or various other genes referenced below, in part by generating or using a target variant reference set that includes both marker variants and target variant positions with target variant indications for a particular genomic sample.
[0034] The customized genotype imputation system improves genotype detection by utilizing a first-of-its-kind reference group. More specifically, the customized genotype imputation system generates or utilizes a target variant reference group customized with a target variant position specific to one or more target variants. Existing reference groups do not include target variant positions with target variant indications of the presence or absence of target variants on maternal haplotypes and paternal haplotypes. The disclosed target variant reference group facilitates more accurate genotype detection of repeat sequence expansions and other pathogenic variants, including more accurate phased genotype detection, by enabling the customized genotype imputation system to compare nearby marker variants within the nucleotide reads of the target genomic sample with alleles of the haplotype represented by the target variant reference group with corresponding target variant indications.
[0035] In addition to the improved genotype detection of the target variant, in one or more embodiments, by generating a target variant reference group including data of one or more target genomic regions (or genomic regions of interest) corresponding to the target variant, the customized genotype imputation system improves computer processing efficiency and uses less memory relative to the existing reference group. For illustration, in some embodiments, the customized genotype imputation system limits the target variant reference group to data including haplotypes of genomic samples corresponding to one or more target genomic regions corresponding to the target variant, but does not include data representing haplotypes outside the one or more target genomic regions. This improves efficiency and saves computing resources by reducing or eliminating the over-analysis of other genomic coordinates performed by conventional systems. Because some existing reference groups may include a haplotype matrix with 50 million cells representing different marker variants and haplotypes, and existing sequencing systems can determine 40,000 genotype detections based on 40,000 haplotype matrices within the reference group, the relatively small size reduction of the target variant reference group can save considerable memory and computer processing. By reducing or eliminating unnecessary genomic regions and using a target variant reference set that includes data limited to one or more target genomic regions, the customized genotype imputation system uses less memory and speeds up computer processing time for imputing genotype calls of target variants.
[0036] As shown in the above discussion, the present disclosure utilizes a variety of terms to describe the features and advantages of the customized genotype inference system. Additional details about the meaning of such terms are now provided. For example, as used herein, the term "nucleotide read" (or simply "read") refers to a sequence of one or more nucleotide bases (or nuclear base pairs) inferred from all or part of a sample nucleotide sequence. Specifically, the nucleotide read includes a sequence determined or predicted based on a sequencing library corresponding to a genomic sample based on the nuclear base detection of a nucleotide fragment (or a monoclonal nucleotide fragment group). For example, in some cases, the sequencing device determines the nucleotide read by generating a nuclear base detection of a nuclear base passing through a nanopore of a nucleotide sample slide, determined via fluorescent labeling, or determined based on a hole in a circulation pool.
[0037] In addition, as used herein, the term "nucleobase call" (or sometimes simply "base call") refers to the determination or prediction of a specific nucleotide base (or nucleotide pair) for a genomic coordinate of a sample genome or for an oligonucleotide or for a genomic coordinate of a sample genome during a sequencing cycle. Specifically, a nucleobase call can indicate: (i) the determination or prediction of the type of nucleobase that has been incorporated into an oligonucleotide on a nucleotide sample slide (e.g., a read-based nucleobase call); or (ii) the determination or prediction of the type of nucleobase present at a genomic coordinate or region within a genome, including variant calls or non-variant calls in a digital output file. In some cases, for a nucleotide read, a nucleobase call includes determining or predicting a nucleobase based on an intensity value generated by a fluorescently labeled nucleotide of an oligonucleotide added to a nucleotide sample slide (e.g., in a cluster of a flow cell). Alternatively, a nucleobase call includes determining or predicting a nucleobase based on a chromatographic peak or current change that is generated by a nucleotide passing through a nanopore of a nucleotide sample slide. In contrast, based on the nucleotide reads corresponding to the genomic coordinates, the nucleobase call may also include the nucleobase at the genomic coordinates of the sample genome of the final predicted variant call file (VCF) or other base call output file. Therefore, the nucleobase call may include base calls corresponding to the genomic coordinates and the reference genome, such as an indication of a variant or non-variant at a specific position corresponding to the reference genome. In fact, the nucleobase call may refer to a variant call, including but not limited to a single nucleotide variant (SNV), an insertion or deletion (indel), or a base call as part of a structural variant. As mentioned above, a single nucleobase call may be an adenine (A) call, a cytosine (C) call, a guanine (G) call, or a thymine (T) call.
[0038] In addition, as used herein, the term "variant" refers to one or more nucleobase calls that are different or different from a reference base (or multiple reference bases) of a reference genome. For illustration, variant nucleobase calls may include (or be part of) various structural variants that are different from one or more reference bases of a reference genome. For illustration, variants may include SNPs, deletions, insertions, duplications, inversions, translocations, or copy number variations (CNVs). In one or more embodiments, variants include mutations that include naturally or synthetically introduced mutations, such as CRISPR-induced mutations.
[0039] Relatedly, as used herein, the term "target variant" refers to a variant selected or identified for detection or inference. In some cases, the target variant includes a variant that has been identified for detection by a variant detector, a variant detection model, or other detector. For example, the target variant can be identified by a repeat expansion detection model, a structural variant detector, a CYP2D6 detector, a CNV detector, a small variant detector, or other detectors for detection. As described below, the target variant can be a variant of a specific gene, which includes but is not limited to the replication factor C subunit 1 (RFC1) gene, the cytochrome P450 family 2 subfamily D member 6 (CYP2D6) gene, the cytochrome P450 family 2 subfamily B member 6 (CYP2B6) gene, the cytochrome P450 family 21 subfamily A member 2 (CYP21A2) gene, the survival of motor neuron 1 (SMN1) gene, the survival of motor neuron 2 (SMN2) gene, the glucocerebrosidase beta (GBA) gene, the blood group Rh (CE) (RHCE) gene, the lipoprotein (A) (LPA) gene, the fragile X mental retardation 1 (FMR1) gene, the hexosaminidase subunit alpha (HEXA) gene, the hemoglobin subunit alpha 1 (HBA1) gene, the hemoglobin subunit alpha 2 (HBA2) gene or the hemoglobin subunit beta (HBB) gene.
[0040] In addition, as used herein, the term "infer" refers to statistically inferring or estimating the genotype of a genome coordinate or genome region. More specifically, inferring may include statistically inferring the genotype of one or more alleles of the haplotype of the genome region corresponding to the sample genome. For example, inferring may refer to determining the genotype of the alleles of the haplotype corresponding to the genome region using the marker variants around the genome region. In one or more embodiments, the custom genotype inferring system utilizes the reference group and genotype inferring model (e.g., hidden Markov model) from the haplotype database to infer genotype detection. As further described herein, the custom genotype inferring system can be based on the SNP (or other marker variants) that is also a part of one or more haplotypes corresponding to the target genome region around or flank the target genome region to infer the genotype detection of the target variant in the target genome region. For example, if the haplotype shows different groups of SNPs in the target genome region and some genome samples in the target variant reference group also show target variants, the custom genotype inferring system can use such different groups of SNPs and the target variant indication corresponding to the specific haplotype of the genome sample to infer the target genome sample including the target variant.
[0041] As used herein, the term "reference genome" refers to a digital nucleic acid sequence assembled as a representative example (or multiple representative examples) of genes and other genetic sequences of an organism. Regardless of the length of the sequence, in some cases, the reference genome represents an exemplary set of genes or a set of nucleic acid sequences determined to represent the digital nucleic acid sequence of an organism. For example, the linear human reference genome can be GRCh38 (or other versions of the reference genome) from the Genome Reference Alliance. GRCh38 may include alternative continuous sequences representing alternative haplotypes, such as SNPs and small indels (e.g., 10 or fewer base pairs, 50 or fewer base pairs).
[0042] In addition, as used herein, term " reference group " refers to the digital collection or database of haplotype from genomic sample, and one or more ancestors or ancestor haplotypes have been determined for this genomic sample.In some cases, reference group includes the digital database of haplotype from genomic sample, and this genomic sample represents the colony of organism (or common in the colony of organism) and multiple ancestors or ancestor haplotypes have been determined for this genomic sample.Reference group can also include the data file or other data organization form of various variant marks (for example, SNP) reflecting genomic sequence and those genomic sequences.To illustrate, reference group can include the data corresponding to genomic sequence and various labels or other metadata of characterization or classification genomic sequence.In some cases, when generating the reference group indicated by the marker variant of the marker variant at the genomic coordinates of the genomic sample corresponding to different haplotypes, the customized genotype inference system accesses the initial reference group developed by the haplotype reference alliance (HRM), 1000 human genome project or Illumina, Inc.
[0043] In addition, the term "target variant reference group" used herein refers to a reference group of data including genomic sequences of genomic samples from different haplotypes and one or more target variant positions indicated by target variants including one or more target variants. Specifically, the target variant reference group may include a genomic sequence including data indications of various marker variants (e.g., SNPs) and a data field for indicating the presence or absence of one or more target variants. For illustration, the target variant reference group may include various different genomic samples phased as maternal sequences and paternal sequences and a data field representing the target variant position, which indicates the presence or absence of the target variant of both the paternal genomic sequence and the maternal genomic sequence.
[0044] Relatedly, as used herein, the term "target variant position" refers to a data attribute, feature, unit or field for indicating a target variant. Specifically, the term target variant position may include a data unit or data field, wherein a target variant indication may be added or inserted to identify the presence or absence of a target variant in an allele, haplotype or genomic sample. For illustration, a target variant position may include a data field in a target variant reference group, wherein "0" indicates the absence of a target variant and / or wherein "1" indicates the presence of a target variant. In some cases, the target variant reference group includes a target variant position indicated by a target variant of a biallelic target variant. In addition, or in an alternative, in some embodiments, a target variant reference group may include a plurality of target variant positions, and the plurality of target variant positions include a plurality of data entries or other target variant indications of a multi-allelic target variant.
[0045] In addition, as used herein, the term "marker variant" refers to a variant at a polymorphic site in a population. Specifically, a marker variant includes an allele in two or more alleles present in a population at a polymorphic genomic coordinate or genomic region at a frequency greater than a threshold frequency (such as greater than 1% of a population). In some cases, the marker variant includes a SNP present at a polymorphic genomic coordinate in a population represented in a reference group. Additionally or alternatively, the marker variant may include an insertion or deletion (indel), a structural variant, or other variants at a polymorphic site in a population. As described above, the allele of a specific haplotype represented by a reference group may include a SNP or other variant markers for inference.
[0046] Relatedly, as used herein, the term "marker variant indication" refers to a data indication of a marker variant. Similarly, also as used herein, the term "target variant indication" refers to a data indication of a target variant. Specifically, the term marker variant indication may include a "1" indicating the presence of a variant at a specific genome coordinate in a file (e.g., VCF) or a "0" reflecting the absence of a variant at a specific genome coordinate in a file. However, it should be understood that the marker variant indication and / or target variant indication may include additional data indications reflecting the presence or absence of a variant, such as a single letter code, an alphanumeric code, or other symbols.
[0047] In addition, as used herein, the term "genomic coordinates" refers to a specific position or orientation of a nucleotide base in a genome (e.g., a genome or reference genome of an organism). In some cases, the genomic coordinates include an identifier of a specific chromosome of a genome and an identifier of the orientation of a nucleotide base in a specific chromosome. For example, one or more genomic coordinates may include a chromosome number, a name or other identifier (e.g., chr1 or chrX) and one or more specific positions, such as a numbered position after the chromosome identifier (e.g., chr1:1234570 or chr1:1234570-1234870). In addition, in some specific implementations, genomic coordinates refer to the source of a reference genome (e.g., mitochondrial DNA reference genome mt or SARS-CoV-2 reference genome of a SARS-CoV-2 virus) and the position of a nucleotide base in the source of a reference genome (e.g., mt:16568 or SARS-CoV-2:29001). In contrast, in some cases, genomic coordinates refer to the position of a nucleotide base in a reference genome, without reference to a chromosome or source (e.g., 29727).
[0048] In addition, as used herein, the term "genomic region" refers to the range of genomic coordinates. Like genomic coordinates, in certain embodiments, a genomic region can be identified by a chromosome identifier and one or more specific positions, such as the numbered position after the chromosome identifier (e.g., chr1:1234570-1234870).
[0049] Relatedly, the term "target genomic region" refers to a genomic region that includes a target variant and the nucleobases surrounding or flanking the target variant. Specifically, the target genomic region may include the genomic coordinates of the target variant and at least the genomic coordinates of the marker variant within a threshold number of nucleobases (e.g., 50 base pairs, 200 base pairs, 500 base pairs, 1,000 base pairs) upstream of the target genomic region and / or within a threshold number of nucleobases (e.g., 50 base pairs, 200 base pairs, 500 base pairs, 1,000 base pairs) downstream of the target genomic region.
[0050] Also as used herein, the term "haplotype" refers to a nucleotide sequence present in an organism (or present in an organism from a population) and inherited from one or more ancestors. Specifically, a haplotype may include alleles or other nucleotide sequences present in organisms of a population and inherited together by these organisms from a single parent, respectively. In one or more embodiments, a haplotype includes a group of SNPs that tend to be inherited together on the same chromosome. In some cases, data representing a haplotype or a group of different haplotypes are stored on a haplotype database or otherwise accessible on a haplotype database.
[0051] In addition, as used herein, the term "genomic sample" refers to a target genome or a portion of a genome that is subjected to sequencing. For example, a sample genome includes a nucleotide sequence (or a copy of such a separated or extracted sequence) isolated or extracted from a sample organism. Specifically, a sample genome includes a whole genome that is isolated or extracted (in whole or in part) from a sample organism and consists of nitrogen-containing heterocyclic bases. The sample genome may include fragments of deoxyribonucleic acid (DNA), ribonucleic acid (RNA), or other polymeric forms of nucleic acids or chimeric or hybrid forms of nucleic acids described below. In some cases, the sample genome is present in a sample prepared or separated by a kit and received by a sequencing device.
[0052] Relatedly, the term "allele" refers to a version of a nucleobase or nucleotide sequence at a genomic coordinate or genomic region corresponding to a haplotype (such as a genomic region encoding a gene or a haplotype of a non-coding region). Specifically, an allele includes one of two or more versions of a nucleobase or nucleotide sequence at a genomic coordinate or region that tend to be inherited in combination as part of a haplotype. As part of a haplotype, in some cases, a combination of alleles can be inherited by an organism as part of a single gene or across multiple genes.
[0053] In addition, as used herein, the term "genetic diversity" refers to a range of different genetic variants within a population. Specifically, genetic diversity includes a range of genetic variants exhibited by different haplotypes representing different ancestries, continents, countries and / or populations. More specifically, a reference set may include data representing haplotypes that exhibit genetic diversity in variants within the alleles of a haplotype.
[0054] Additional details will now be provided in conjunction with the illustrative drawings that depict exemplary embodiments and implementations of the persona group system. For example, Figure 1 A schematic diagram of a computing system 100 in which a custom genotype imputation system 104 and a sequencing system 106 operate according to one or more embodiments is shown. As shown, the computing system 100 includes one or more server devices 102 connected to user client devices 108 and sequencing devices 114 via a network 112. Figure 1 An embodiment of a customized genotype imputation system 104 is shown, but the present disclosure describes the following alternative embodiments and configurations.
[0055] like Figure 1 As shown in FIG. 1 , server device 102, user client device 108, and sequencing device 114 are connected via network 112. Thus, each component of computing system 100 can communicate via network 112. Network 112 includes any suitable network over which computing devices can communicate. Fig.12 The example network is discussed in more detail.
[0056] like Figure 1As shown, the sequencing device 114 includes a device for sequencing a genomic sample or other nucleic acid polymer. In some embodiments, the sequencing device 114 analyzes oligonucleotides extracted from the genomic sample to generate data directly or indirectly on the sequencing device 114 using computer-implemented methods and systems (described herein). More specifically, the sequencing device 114 receives and analyzes nucleic acid sequences extracted from the genomic sample in a nucleotide sample slide (e.g., a circulation pool). In one or more embodiments, the sequencing device 114 utilizes SBS to sequence the genomic sample or other nucleic acid polymer. In addition or in lieu of communicating across the network 112, in some embodiments, the sequencing device 114 bypasses the network 112 and communicates directly with the user client device 108. In addition, as Figure 1 As shown, in one or more embodiments, the sequencing device 114 includes a custom genotype estimation system 104 .
[0057] like Figure 1 As further shown, the server device 102 can generate, receive, analyze, store and transmit digital data, such as data for nucleobase calls or nucleotide reads. Figure 1 As shown, the sequencing device 114 can send (and the server device 102 can receive) various data from the sequencing device 114, including data representing nucleotide reads. The server device 102 can also communicate with the user client device 108. Specifically, the server device 102 can send nucleotide reads, base calls, genomic samples and / or reference groups to the user client device 108. In addition, as shown in FIG. Figure 1 As shown, the server device 102 may include a custom genotype imputation system 104. In one or more embodiments, as further explained below, the custom genotype imputation system 104 generates a target variant reference group including one or more target variant positions. Therefore, the server device 102 may also send data representing the target variant reference group to the user client device 108.
[0058] In some embodiments, server device 102 comprises a distributed collection of servers, where server device 102 includes many server devices distributed across network 112 and located in the same or different physical locations. In addition, server device 102 may include a content server, an application server, a communication server, a web hosting server, or another type of server.
[0059] In some cases, the server device 102 is located at or near the same physical location as the sequencing device 114 or remote from the sequencing device 114. In fact, in some embodiments, the server device 102 and the sequencing device 114 are integrated into the same computing device. The server device 102 can run the sequencing system 106 or the custom genotype imputation system 104 to generate, receive, analyze, store, and send digital data, such as by receiving base call data or determining variant calls based on analyzing such base call data.
[0060] like Figure 1 As further shown and indicated in the accompanying drawings, the user client device 108 can generate, store, receive and transmit digital data. Specifically, the user client device 108 can receive data about nucleotide reads, nucleobase calls, genotype calls, sequencing metrics and / or target variant reference sets from the server device 102 and / or the sequencing device 114. The user client device 108 can therefore present data about genotype calls to a user associated with the user client device 108 within a graphical user interface.
[0061] Figure 1 The user client device 108 shown in FIG. 1 may include various types of client devices. For example, in some embodiments, the user client device 108 includes a non-mobile device, such as a desktop computer or server, or other types of client devices. In still other embodiments, the user client device 108 includes a mobile device, such as a laptop, a tablet computer, a mobile phone, or a smart phone. Additional details about the user client device 108 are described below in conjunction with Fig.12 Discussion.
[0062] like Figure 1 As further shown, the user client device 108 includes a sequencing application 110. The sequencing application 110 may be a web application or a native application (e.g., a mobile application, a desktop application) stored and executed on the user client device 108. The sequencing application 110 may include instructions that, when executed, cause the user client device 108 to receive data from the custom genotype imputation system 104 and present data from the sequencing device 114 and / or the server device 102. In addition, the sequencing application 110 may instruct the user client device 108 to display data of genotype calls, such as genotype calls of target variants from a variant call file (VCF).
[0063] like Figure 1As further shown in , the customized genotype imputation system 104 can be located on the user client device 108 as part of the sequencing application 110 or on the sequencing device 114. Thus, in some embodiments, the customized genotype imputation system 104 is implemented by (e.g., completely or partially located at) the user client device 108. As mentioned, in yet other embodiments, the customized genotype imputation system 104 is implemented by one or more other components of the computing system 100 (e.g., the sequencing device 114). Specifically, the customized genotype imputation system 104 can be implemented across the server device 102, the network 112, the user client device 108, and the sequencing device 114 in a variety of different ways.
[0064] although Figure 1 The components of the computing system 100 are shown communicating via the network 112, but in some implementations, the components of the computing system 100 may also bypass the network and communicate directly with each other. For example, and as previously described, in some embodiments, the user client device 108 communicates directly with the sequencing device 114. Additionally, in some embodiments, the user client device 108 communicates directly with the custom genotype imputation system 104. Additionally, the custom genotype imputation system 104 may access one or more databases hosted on or accessed by the server device 102 or elsewhere in the computing system 100.
[0065] As described above, in one or more embodiments, the custom genotype imputation system 104 generates and / or utilizes a target variant reference set to impute genotype calls. According to one or more embodiments, Figure 2A An overview of a custom genotype imputation system 104 for generating a target variant reference set of target variants is shown, and Figure 2B An overview of a custom genotype imputation system 104 that utilizes a target variant reference set to impute genotype calls for target variants is shown.
[0066] like Figure 2A As shown, for example, the custom genotype imputation system 104 generates a reference set 202. The reference set 202 includes digital representations of haplotypes from genomic sample 200a, genomic sample 200b, and genomic sample 200c. Although for illustrative purposes, Figure 2A Three genomic samples are included, but it should be understood that in one or more embodiments, the reference set 202 can include various amounts of various different genomic samples.
[0067] Also like Figure 2AAs shown, the custom genotype imputation system 104 can generate a reference set 202 to include phased alleles of genomic samples 200a to genomic samples 200c. To illustrate, the custom genotype imputation system 104 can determine which alleles from genomic samples 200a to genomic samples 200c correspond to maternal haplotypes and paternal haplotypes. Figure 2A As shown, reference set 202 can include a maternal copy and a paternal copy of each allele.
[0068] In addition to the different haplotypes from genome sample 200a to genome sample 200c, as Figure 2A As further shown, the custom genotype imputation system 104 generates a reference set 202 including marker variants, such as SNPs and small indels (e.g., 10 or fewer base pairs, 50 or fewer base pairs). To mark each marker variant in the corresponding genomic sample, the reference set 202 includes a marker variant indication 201a, a marker variant indication 201b, a marker variant indication 201c, and a marker variant indication 201d at the genomic coordinates of the corresponding marker variant. Specifically, Figure 2A Open or unfilled circles within the alleles of each genomic sample of genomic sample 200a to genomic sample 200c are shown to represent marker variant indications 201a to marker variant indications 201d. For illustrative purposes, an open or unfilled circle indicates that a particular allele of a genomic sample includes a marker variant indication of a corresponding marker variant, and the absence of such an open or unfilled circle indicates that a particular allele of a genomic sample does not include a marker variant indication of a corresponding marker variant. In fact, in one or more embodiments, reference group 202 includes data indications of other marker variant indications of marker variants present on either or both alleles corresponding to a maternal haplotype or a paternal haplotype.
[0069] Also like Figure 2A As shown, the custom genotype imputation system 104 adds the target variant position 204 to the reference group 202. More specifically, the custom genotype imputation system 104 adds the target variant position 204 to the reference group 202 as part of generating the target variant reference group. In one or more embodiments, the target variant position 204 is a data field used to indicate whether the target variant exists for the maternal allele and the paternal allele of the genomic sample. Specifically, Figure 2A Dashed circles are shown next to the alleles of genomic samples 200a to genomic samples 200c to represent target variant positions 204. In practice, Figure 2A As shown, the custom genotype imputation system 104 adds a target variant position 204 for each genomic sample or for each allele of each genomic sample.
[0070] After adding target variant position 204, Figure 2A As further shown, the custom genotype imputation system 104 phases the alleles 206 of the genomic samples 200a to genomic samples 200c. More specifically, in one or more embodiments, the custom genotype imputation system 104 phases the alleles associated with the target variant to identify a genomic sequence that includes the target variant for either or both the maternal allele and the paternal allele. Thus, the custom genotype imputation system 104 can identify the presence or absence of the target variant for the maternal allele and the paternal allele of each genomic sample in the target variant reference group. Figure 2A As shown, for example, the phased alleles 206 for genomic samples 200a through genomic samples 200c include different patterns indicative of different alleles corresponding to different haplotypes.
[0071] In addition to phasing the alleles of different genomic samples, in one or more embodiments, the custom genotype imputation system 104 adds a target variant indication in the target variant position 204. Specifically, Figure 2A The filled black circles next to the alleles of genomic samples 200a to genomic samples 200c are shown to represent the target variant indications within the target variant position 204 to indicate that the target variant is present in a specific allele. In fact, the custom genotype imputation system 104 generates a target variant indication indicating whether the genomic sample includes the target variant. In addition, in one or more embodiments, the custom genotype imputation system 104 adds the indication to the target variant position 204 of either the maternal allele and the paternal allele of each genomic sample in the target variant reference group.
[0072] By adding the target variant indication to the target variant position 204 and phasing the alleles of the genomic sample 200a to the genomic sample 200c, the custom genotype imputation system 104 generates a target variant reference set 208 including the target variant indication in the target variant position. Thus, the target variant reference set 208 includes data on the target variant at each allele associated with the target variant. For example, Figure 2A As shown, the target variant reference set 208 is represented as a file. In practice, in one or more embodiments, the custom genotype imputation system 104 generates a VCF with the target variant positions 204 as rows in the VCF and the target variant indications as "0" for unaffected alleles and "1" for affected alleles.
[0073] Now turn to Figure 2B , the custom genotype estimation system 104 can use the target variant reference set to estimate the genotype call indicating the presence or absence of the target variant in the target genomic sample 216. For illustration, Figure 2BAs shown, the custom genotype imputation system 104 identifies nucleotide reads 210 corresponding to the target genomic sample 216. In one or more embodiments, the custom genotype imputation system 104 utilizes a sequencing system and / or one or more sequencing devices to identify nucleic acid fragments or oligonucleotides extracted from the genomic sample to generate data. For illustration, in some embodiments, the sequencing device or the custom genotype imputation system 104 receives and analyzes oligonucleotides extracted from the target genomic sample 216 in a nucleotide sample slide (e.g., a flow cell). In addition, or in an alternative, the custom genotype imputation system 104 may receive nucleotide reads of the target genomic sample 216 from a third-party sequencing system or from a sequencing device controlled by a separate entity.
[0074] Also like Figure 2B As shown, the custom genotype imputation system 104 can compare the nucleotide reads 210 to the reference genome 212 to determine variant calls or sequences within a specific genomic region of the target genomic sample 216. In addition, the custom genotype imputation system 104 can identify one or more aligned nucleotide reads of the target genomic region corresponding to the target variant. Because the alignment of the nucleotide reads 210 to the reference genome 212 may produce inaccurate variant calls or no calls for some genomic regions, the custom genotype imputation system 104 can rely on the target variant reference group 214 as a substitute for nucleotide reads covering the target genomic region. Therefore, as Figure 2B As shown, the custom genotype imputation system 104 can also utilize the target variant reference set 214 to determine the genotype calls of the target genomic sample 216, especially the genotype calls of the difficult-to-call genomic regions.
[0075] like Figure 2B As shown, for example, the custom genotype imputation system 104 accesses a target variant reference group 214. To illustrate, in one or more embodiments, the custom genotype imputation system 104 compares (i) a marker variant represented by a subset of aligned nucleotide reads and flanking or surrounding a target genomic region of a target variant with (ii) a corresponding marker variant within an allele of a genomic sample 200a to a genomic sample 200c represented by the target variant reference group 214. To illustrate such marker variants, the target variant reference group 214 includes marker variant indications 201a, 201b, 201c, and 201d within the alleles of genomic samples 200a, 200b, and 200c. As described above, an open or unfilled circle indicates that a particular allele of a genomic sample includes a marker variant indication of a corresponding marker variant, and the absence of such an open or unfilled circle indicates that a particular allele of a genomic sample does not include a marker variant indication of a corresponding marker variant.
[0076] like Figure 2B As further shown, both genomic sample 200c and target genomic sample 216 include open or unfilled circles, which indicate marker variants corresponding to marker variant indication 201a on both maternal alleles and paternal alleles. In contrast, both genomic sample 200c and target genomic sample 216 include a single open or unfilled circle, which indicates a marker variant corresponding to marker variant indication 201a on a single allele. The marker variant indication 201c and marker variant indication 201d of genomic sample 200c and target genomic sample 216 do not include such open or unfilled circles to indicate that their alleles do not include the corresponding marker variants.
[0077] In order to facilitate the comparison of marker variants between the target genome sample 216 and the genome samples 200a to genomic samples 200c represented by the target variant reference group 214, the customized genotype imputation system 104 can limit the marker variants of the comparison to the threshold distance from the target variant. In fact, in one or more embodiments, the customized genotype imputation system 104 identifies marker variants within the threshold number of nucleobases from the target variant or target genome region. For example, in some cases, the customized genotype imputation system 104 (i) identifies marker variants within the threshold number of nucleobases (e.g., 10 nucleobases, 50 nucleobases, 200 nucleobases) upstream of the target genome region and / or (ii) identifies marker variants within the threshold number of nucleobases (e.g., 10 nucleobases, 50 nucleobases, 200 nucleobases) downstream of the target genome region.
[0078] Based on comparing such marker variants, the custom genotype imputation system 104 can phase the nucleotide reads of the target genomic sample 216 to identify corresponding alleles in the maternal haplotype and the paternal haplotype. As shown by the different patterns indicating different alleles in the target variant reference set 214, for example, the alleles of the target genomic sample 216 include the same marker variants as the alleles of the genomic sample 200c.
[0079] like Figure 2BAs further shown, the custom genotype imputation system 104 can impute the genotype call 218 of the target variant within the target genome sample by comparing the marker variant of the target variant reference group with the marker variant of the target genome sample. More specifically, the custom genotype imputation system 104 determines the genotype call 218 by statistically inferring the haplotype (e.g., represented as a value between 0 and 1) that may be present at the genomic region of the target genome sample based on the target variant reference group 214. For illustration, the custom genotype imputation system 104 uses statistical inference and includes the haplotype of the marker variant from the target variant reference group 214 to identify the haplotype that may be present at the genomic region from the target variant reference group. In addition, the custom genotype imputation system 104 can use the identified haplotype from the target variant reference group 214 to determine the genotype call of the target genome sample.
[0080] As described above, many existing sequencing systems fail to make genotype calls or make inaccurate genotype calls for difficult-to-call genomic regions, including regions with repetitive sequence expansions. Figure 3 Such difficult-to-detect genomic regions are shown. More specifically, Figure 3 Nucleotide reads of a genomic sample that are not aligned to a genomic region comprising a repetitive sequence expansion according to one or more embodiments are shown.
[0081] like Figure 3 As shown, for example, the sequencing system aligns nucleotide reads corresponding to genomic sample 300a (e.g., HG04127) and genomic sample 300b (e.g., HG01506) to (i) the target genomic region 302 and the reference genome corresponding to the repeat sequence expansion of the RFC1 gene and (ii) the surrounding genomic region 304a and genomic region 304b adjacent to the target genomic region 302. Both genomic sample 300a and genomic sample 300b are putative carriers of the repeat sequence expansion variant corresponding to the target genomic region 302. As shown, the sequencing system aligns the nucleotide reads of genomic sample 300a having at least 10 times coverage of genomic sample 300a to the surrounding genomic region 304a and genomic region 304b, but does not consistently align the nucleotide reads of genomic sample 300a to the target genomic region 302. Similarly, the sequencing system aligns the nucleotide reads of genome sample 300b having at least 4-fold coverage of genome sample 300b to the surrounding genomic region 304a and genomic region 304b, but inconsistently aligns the nucleotide reads of genome sample 300b to the target genomic region 302. Although both genome sample 300a and genome sample 300b are putative carriers of the repeat expansion variant, the alignment exhibits a read coverage gap within the target genomic region 302.
[0082] therefore, Figure 3 Poor nucleotide read data quality is shown, which is characteristic of some genomic regions that exhibit repetitive sequence expansion. In some cases, it is impossible to accurately identify such expanded repetitive sequences in genomic samples carrying target variants using existing sequencing systems. More specifically, due to the nature of repetitive sequences that give multiple possible alignments, alignment of nucleotide reads to the reference genome in target genomic region 302 is uncertain or impossible. For example, Figure 3 As shown, genome sample 300a and genome sample 300b exhibit approximately 35 and 33 AAGGG repeating units, respectively, within target genome region 302. For example, because a nucleotide fragment indicating "AGGGAAGGGAAG" may have multiple alignments, existing sequencing systems find it difficult or even impossible to align the corresponding nucleotide reads with the target genome region 302 of the reference genome and determine the length of the repeat sequence expansion.
[0083] As described above, the customized genotype estimation system 104 can use the target variant reference group to estimate the genotype call of the target variant more accurately than the existing sequencing system, especially the genotype call of the genomic region that is difficult to detect. According to one or more embodiments, Figure 4 A unified manifold approximation and projection (UMAP) plot 400 is shown representing data points of various genomic samples clustered according to SNPs or other marker variants. As shown by the target variant clusters 410 in the UMAP plot 400, genomic samples affected by the target variant tend to cluster together based on shared marker variants.
[0084] like Figure 4 As shown, in one or more embodiments, the custom genotype imputation system 104 performs principal component analysis (PCA) to cluster the genomic samples based on the SNPs or other marker variants present in each genomic sample. The custom genotype imputation system 104 also uses UMAP to visualize the clusters of genomic samples. UMAP graph 400 shows the results of such clustering.
[0085] like Figure 4As depicted, for example, UMAP graph 400 shows data points representing various genomic samples along UMAP-3D-One axis 404 and UMAP-3D-Two axis 402 via dimensionality reduction. As indicated by the black filled circles indicating specific data points, UMAP graph 400 includes data points representing genomic samples carrying variants 406 of the RFC1 gene including pathogenic repeat sequence expansion. Specifically, the customized genotype inference system 104 identifies a target variant cluster 410 including data points representing genomic samples, which include at least one allele of the target variant with the RFC1 gene. In contrast, as indicated by the lighter filled circles or gray circles representing specific data points, UMAP graph 400 also includes data points representing genomic samples exhibiting non-variants 408 (or in other words, genomic samples not affected by the target variant of the RFC1 gene).
[0086] Therefore, UMAP figure 400 shows that SNP or other marker variants constitute reliable evidence for the genotype detection of RFC1 inferred target variants. For illustration, genomic samples from target variant cluster 410, because they not only show the same or similar nucleotides at the target genomic region of RFC1, but also show similar or identical SNPs at other genomic regions flanking or surrounding the target genomic region (e.g., within 200 base pairs upstream or downstream of the target genomic region). Therefore, UMAP figure 400 shows that SNP can be used to infer or identify the proof of concept of genomic samples showing RFC1 pathogenic repeat sequences.
[0087] To exploit such concepts using a unique reference set specific to a target variant, the custom genotype imputation system 104 can generate a target variant reference set that includes the target variant position. According to one or more embodiments, Figure 5 The custom genotype imputation system 104 is shown generating a reference group 502 and adding a target variant position 518 to the reference group 502 to generate a target variant reference group 524. As explained below, the custom genotype imputation system 104 can generate a target variant reference group 524 that includes (i) phased alleles corresponding to the target variant indication within the target variant position 518, and (ii) marker variant indications of marker variants phased according to the maternal haplotype and the paternal haplotype of the genomic sample.
[0088] like Figure 5As shown, the custom genotype imputation system 104 generates a reference group 502 including genomic samples 504, genomic samples 506, and genomic samples 508 of different haplotypes. Specifically, the reference group 502 includes alleles of genomic samples 504 to genomic samples 508, and the alleles of genomic samples 504 to genomic samples 508 include marker variant indications of SNP 510, SNP 512, and SNP 516. However, it should be understood that genomic samples 504 to genomic samples 508 and SNP 510 to SNP 516 are given by way of example, and the custom genotype imputation system 104 can generate reference groups and / or target variant reference groups including various numbers of SNPs and genomic samples, including genomic samples representing hundreds or thousands of haplotypes and thousands of SNPs (e.g., 50,000 SNPs; 100,000 SNPs).
[0089] As described above, in one or more embodiments, the custom genotype imputation system 104 generates a reference group 502 including genomic samples having a plurality of different haplotypes exhibiting genetic diversity. For illustration, the custom genotype imputation system 104 may generate a reference group 502 including genomic samples 504 to genomic samples 508 from a plurality of ancestral, continental, national, and / or population groups. Similarly, the custom genotype imputation system 104 may convert the reference group 502 into a target variant reference group including genomic samples 504 to genomic samples 508 having marker variants from a plurality of different ancestral, continental, national, and / or population groups.
[0090] As described above, in one or more embodiments, the custom genotype imputation system 104 can generate an output file (e.g., VCF) including data representing the reference group 502 and / or the target variant reference group 524. However, for purposes of illustration, Figure 5 Reference group 502 and target variant reference group 524 are depicted as a collection of lines representing haplotypes of genomic samples 504 to genomic samples 508 and circles representing marker variant indications indicating the presence of SNPs 510 to SNP 512. As shown by the open or hollow circles representing marker variant indications, genomic sample 504 includes SNP 510 for both maternal and paternal alleles, SNP 512 for both maternal and paternal alleles, and one copy of SNP 516. In contrast, genomic sample 506 includes one copy of SNP 512 and SNP 516 included on both maternal and paternal alleles. Also as shown in FIG. Figure 5 As shown, genomic sample 508 includes SNP 510 on both the maternal allele and the paternal allele and includes one copy of SNP 512.
[0091] Although Figure 5 The marker variant indications of SNPs are shown as open or hollow circles, but it should be understood that in one or more embodiments, the reference group 502 and / or the target variant reference group 524 can be represented in an output file (e.g., VCF) that includes a data field where "0" reflects the reference nucleobase and "1" reflects the alternative nucleobase. In addition, or in an alternative, the custom genotype imputation system 104 can utilize an alternative binary scheme for marker variant indications. For example, the custom genotype imputation system 104 may generate a reference group 502 and / or a target variant reference group 524 including two cells or positions for a multi-allelic marker variant, wherein the "0" indicated as a marker variant in both positions reflects the reference nucleobase, the "0" and "1" indicated as a marker variant in the first position and the second position reflect the first alternative nucleobase, the "1" and "1" indicated as a marker variant in the first position and the second position reflect the second alternative nucleobase, and the "1" and "0" indicated as a marker variant in the first position and the second position reflect the third alternative nucleobase. Alternatively, as yet another example, in some embodiments, the custom genotype imputation system 104 may generate a reference group 502 and / or a target variant reference group 524 including a single cell or position for a multi-allelic marker variant, wherein the value "0" reflects the reference nucleobase, "1" reflects the first alternative nucleobase, "2" reflects the second alternative nucleobase, and / or "3" reflects the third alternative nucleobase.
[0092] like Figure 5 As further shown, the custom genotype imputation system 104 utilizes SNP 510 to SNP 516 as marker variants for imputing genotype calls for the presence or absence of target variants within the target genomic sample. However, in one or more embodiments, the custom genotype imputation system 104 may utilize other marker variants, such as marker variants in the form of deletions, insertions, duplications, inversions, translocations, or CNVs. In some cases, the custom genotype imputation system 104 may generate a reference group 502 that includes a data field having values (e.g., a sequence of values) identifying a plurality of marker variant types.
[0093] like Figure 5 As shown, the custom genotype imputation system 104 generates a target variant reference set 524 in part by adding target variant positions 518. As briefly mentioned above, the target variant position 518 can correspond to a variety of target variants. For example, the target variant may include a biallelic variant or a multi-allelic variant. In addition, in one or more embodiments, the target variant includes a repeat sequence expansion, such as an STR expansion or a VNTR expansion. Regardless of whether the target variant constitutes a repeat sequence expansion, in some cases, the target variant constitutes a pathogenic variant.
[0094] More specifically, in one or more embodiments, the target variants may include variants of various genes. To illustrate, in some embodiments, the target variants may include, but are not limited to, a replication factor C subunit 1 (RFC1) gene, a cytochrome P450 family 2 subfamily D member 6 (CYP2D6) gene, a cytochrome P450 family 2 subfamily B member 6 (CYP2B6) gene, a cytochrome P450 family 21 subfamily A member 2 (CYP21A2) gene, a motor neuron survival 1 (SMN1) gene, a motor neuron survival 2 (SMN2) gene, a glucocerebrosidase β (GBA) gene, a blood group Rh (CE) (RHCE) gene, a lipoprotein (A) (LPA) gene, a fragile X mental retardation 1 (FMR1) gene, a hexosaminidase subunit α (HEXA) gene, a hemoglobin subunit α1 (HBA1) gene, a hemoglobin subunit α2 (HBA2) gene, or a hemoglobin subunit β (HBB) gene variant.
[0095] Regardless of the gene or target genomic region, in some embodiments, the target variant may include a deletion, insertion, duplication, inversion, translocation or CNV that is propagated within the population. To illustrate, in one or more embodiments, the custom genotype imputation system 104 uses target variants inherited from ancestral haplotypes to support sufficient data for a target variant reference group with a target variant position specific to the target variant. Therefore, in some embodiments, the new variant may not support the target variant reference group. Because the custom genotype imputation system 104 detects variants based on a target variant reference group including various genomic samples, the new mutation in the target genomic sample will not be present in a sufficient number of haplotypes to support the functional version of the target variant reference group. Therefore, the new variant will not be present in the target variant reference group or will only have limited representation therein.
[0096] To ensure sufficient haplotype data, in one or more embodiments, the custom genotype imputation system 104 uses a target variant reference group specific to the target variant that meets one or more thresholds. For example, in some cases, depending on the number of genomic samples in the target variant reference group, the target variant must meet one or more relative thresholds, including a threshold carrier rate, a threshold linkage disequilibrium (LD) with respect to a specific marker variant, or a threshold mutation rate. To support imputed genotype calls, in one or more embodiments where the target variant reference group represents approximately 3,000 genomic samples, the target variant must exhibit a threshold carrier rate of approximately 2% of the genomic samples; have an r with a SNP or other marker variant; 2 A threshold LD of 0.75, thus simulating a strong founder effect, and 1.29 × 10 per base pair per meiosis -8 The threshold mutation rate for each mutation.
[0097] In fact, in some embodiments, the custom genotype imputation system 104 determines a threshold carrier rate, a threshold linkage disequilibrium, or a threshold mutation rate relative to the number of genomic samples represented by the target variant reference group. For example, a target variant reference group representing a relatively large number of genomic samples may be advantageous for a relatively low threshold carrier rate, a relatively low threshold linkage disequilibrium, or a relatively low threshold mutation rate. Therefore, for the threshold carrier rate, threshold LD, or threshold mutation rate, other suitable measurements different from the examples provided above may be used. As described below, depending on the number of genomic samples represented by the target variant reference group, Figure 7 Examples of different threshold carriage rates for target variants are provided.
[0098] like Figure 5 As further shown, in one or more embodiments, the custom genotype imputation system 104 adds the target variant position 518 to the reference set 502 by adding one or more data fields associated with the target variant. As described above, the custom genotype imputation system 104 can generate the target variant reference set 524 as a VCF file, and can use various binary schemes to indicate the nucleotides at the genomic coordinates. To illustrate, in some embodiments, each target variant position 518 can be a field including a target variant indication of "0" or "1", where "0" represents the reference nucleobase and "1" represents an alternative nucleobase.
[0099] By using a variety of different target variant indicators, the custom genotyping system 104 can generate a target variant reference set for a biallelic target variant or a multi-allelic target variant. For example, by using two fields for two target variant positions, the custom genotyping system 104 can represent a multi-allelic target variant. In practice, Figure 5 As shown, a pair of dashed circles in each allele of genomic sample 504, genomic sample 506, and genomic sample 508 represent the target variant position 518 as two target variant positions (e.g., data fields), which together may include or facilitate a binary code indicating the presence or absence of a multi-allelic target variant for a given genomic sample.
[0100] To illustrate how such binary codes in two target variant positions indicate multi-allelic target variants, in some embodiments, "0" indicated as a target variant in two target variant positions represents a reference nucleobase (e.g., A). In contrast, "0" indicated as a target variant in the first target variant position and "1" indicated as a target variant in the second target variant position represent a first alternative nucleobase (e.g., G). In addition, "1" indicated as a target variant in the first target variant position and "1" indicated as a target variant in the second target variant position represent a second alternative nucleobase (e.g., T). "1" indicated as a target variant in the first target variant position and "0" indicated as a target variant in the second target variant position represent a third alternative nucleobase (e.g., C).
[0101] As an alternative to multiple target variant positions, in some embodiments, the custom genotype imputation system 104 uses a non-binary code in a single target variant position to indicate the presence or absence of a multi-allelic target variant. Figure 5 Not indicated, but in some embodiments, a "0" indicated as a target variant in a target variant position represents a reference nucleobase (e.g., A), a "1" indicated as a target variant in a target variant position represents a first alternative nucleobase (e.g., G), a "2" indicated as a target variant in a target variant position represents a second alternative nucleobase (e.g., T), and a "3" indicated as a target variant in a target variant position represents the first alternative nucleobase (e.g., G).
[0102] like Figure 5 As shown, for example, the target variant reference set 524 includes a target variant indication 526a and a target variant indication 526b as a black-filled circle on one allele and a target variant indication 528a and a target variant indication 528b as a black-filled circle on another allele to indicate that the genomic sample 504 includes a specific haplotype of a multi-allelic target variant on both the maternal allele and the paternal allele. Conversely, the target variant reference set 524 includes a pair of dashed circles on two alleles of the genomic sample 506 to indicate that the genomic sample 506 does not include a multi-allelic target variant on the maternal allele or the paternal allele. In addition, the target variant reference group 524 includes a target variant indication 550, which is indicated as a filled black circle on an allele of the genomic sample 508 to indicate that the genomic sample 508 includes a copy of the multi-allelic target variant on the maternal allele or the paternal allele, and as a dashed circle on an allele of the genomic sample 508 to indicate that the genomic sample 508 does not include the multi-allelic target variant on one allele.
[0103] like Figure 5As further shown, in addition to adding the target variant position 518, in some embodiments, the custom genotype imputation system 104 phases the alleles of the genomic sample 504 to the genomic sample 508 together with the target variant indication in the target variant position. By phasing the alleles of the genomic sample 504 to the genomic sample 508, the custom genotype imputation system 104 determines the presence or absence of the target variant in the corresponding alleles present on the maternal haplotype and the paternal haplotype of the genomic sample 504 to the genomic sample 508. In order to phase such alleles, in some cases, the custom genotype imputation system 104 executes a haplotype phasing model, such as a segmented haplotype estimation and imputation tool (SHAPEIT), to estimate haplotypes from the genotype data corresponding to the genomic sample 504 to the genomic sample 508.
[0104] Because both alleles of the homozygous genomic sample include a copy of the target variant and a corresponding target variant indication in the target variant reference group, in some embodiments, the customized genotype imputation system 104 phases the heterozygous alleles of a subset of genomic samples (such as genomic sample 508), where the allele is heterozygous for the target variant. In fact, in some cases, the customized genotype imputation system 104 does not phase the homozygous alleles of a subset of genomic samples (such as genomic sample 504 and genomic sample 506). In contrast, in some embodiments, the customized genotype imputation system 104 executes a haplotype phasing model to phase the alleles of the genomic sample represented by the target variant reference group 524, regardless of the zygosity of the genomic sample for the target variant, wherein the data representing the alleles phased in the target variant reference group also include the target variant indication in the target variant position of the target variant.
[0105] like Figure 5 As further shown, the custom genotype imputation system 104 can compare the nucleotide reads of the target genomic sample 532 to the target variant reference set 524. Figure 8 As discussed, the custom genotype imputation system 104 can use the target variant reference set 524 to impute genotype calls for target variants within the target genomic sample. More specifically, the custom genotype imputation system 104 can use the target variant reference set 524 to determine phased genotype calls for both the maternal copy and the paternal copy from the target genomic sample 532.
[0106] like Figure 5As shown, the custom genotype imputation system 104 generates a genotype call that the target genomic sample 532 includes the multi-allelic target variant and exhibits the same haplotype as the genomic sample 508. In fact, similar to the genomic sample 508, the target genomic sample 532 includes a target variant indication 552 as a filled black circle on an allele to indicate that the target genomic sample 532 includes one copy of the multi-allelic target variant on the maternal allele or the paternal allele, and as a dashed circle on one allele to indicate that the target genomic sample 532 does not include the multi-allelic target variant on one allele.
[0107] As described above, the custom genotype imputation system 104 can generate an output file including a reference set of target variants. According to one or more embodiments, Figure 6 A client device 600 is shown presenting within a graphical user interface a portion of an exemplary VCF including a target variant reference set 601. As explained below, the target variant reference set 601 includes indications of nucleobase calls at genomic coordinates for a plurality of genomic samples and target variant indications in target variant positions that indicate whether a particular allele of the genomic sample exhibits the target variant.
[0108] like Figure 6 As shown, for example, target variant reference set 601 includes a chromosome column 602, a coordinate column 604, a target variant column 605, a reference nucleobase column 606, an alternative nucleobase column 608, a format column 610, and a genomic sample column 612. Figure 6 Client device 600 is shown presenting a portion of target variant reference set 601, but it should be understood that target variant reference set 601 may include information about alleles across the entire genome and the genomic coordinates provided are merely illustrative.
[0109] like Figure 6 As further shown, chromosome column 602 includes chromosome information for each row. Figure 6 , client device 600 presents rows of nucleobase calls for genomic coordinates on chromosome 4. In addition, coordinate column 604 includes partial genomic coordinates for each row, which indicates which genomic coordinates correspond to the nucleobase call information in that row. Figure 6 As shown in the depicted graphical user interface, the client device 600 presents the genomic coordinates from chr4:39348321 to chr4:39348429.
[0110] In addition, the client device 600 presents information about reference nucleobases (e.g., non-variant nucleotide bases) in the reference nucleobase column 606, such as a single letter code (e.g., A, C, T, G) in each cell representing the reference base from the reference genome at the corresponding genomic coordinates. In addition, the client device 600 presents information about alternative nucleobases (e.g., variant nucleotide bases) in the alternative nucleobase column 608, such as a single letter code (e.g., A, C, T, G) in each cell representing the most common alternative nucleobase or the detected alternative nucleobase at the corresponding genomic coordinates.
[0111] like Figure 6 As further shown, the client device 600 also presents information on the format of the nucleobase calls provided in the format column 610 and the values of the phased nucleobase calls in the genomic sample column 612 for the particular genomic sample. Figure 6 As shown, the target variant reference set 601 includes text "GT" that indicates a genotype call format for allele values "0" or "1" in the genomic sample column 612. More specifically, a value of "0" indicates that the nucleobase call is a reference nucleobase from the reference nucleobase column 606. In contrast, a value of "1" indicates that the nucleobase call is an alternative nucleobase from the alternative nucleobase column 608. The "|" symbol between the values in the genomic sample column 612 indicates a phased genotype call.
[0112] In addition to the genotype calls and other genomic coordinates of the marker variants, the client device 600 also presents a target variant column 605 that includes an identifier of the target variant. Figure 6 As shown, the target variant reference group 601 includes an identifier for RCF1 at genomic coordinate chr4:39348425. In some embodiments, chr4:39348425 represents the placeholder genomic coordinates of the target variant position, rather than the actual genomic coordinates within the reference genome. In fact, the row corresponding to chr4:3934825 includes cells or fields representing exemplary target variant positions for each of genomic samples HG00096, genomic samples HG00097, genomic samples HG00099, genomic samples HG00100, and genomic samples HG00101.
[0113] Specifically, as shown in target variant reference group 601, the row corresponding to chr4:3934825 includes "0" and "1" values of target variant indications as the presence or absence of target variants in genomic samples HG00096, genomic samples HG00097, genomic samples HG00099, genomic samples HG00100, and genomic samples HG00101. "0" and "1" values are separated by "|" as a straight bar symbol, and target variant reference group 601 includes phased target variant indications for maternal alleles and paternal alleles of each corresponding genomic sample. Therefore, client device 600 provides information about target variants in target variant reference group 601 via a graphical user interface.
[0114] As part of improving the accuracy of genotype calls for target variants, in some embodiments, the custom genotype imputation system 104 can use a target variant reference set representing a different number of genomic samples. According to one or more embodiments, Figure 7 A graph 700 is shown that plots the non-reference consistency rate at which a sequencing system accurately infers target variants of varying allele frequencies based on a target variant reference set representing a different number of genomic samples. Figure 7 As shown, the non-reference consistency rate curve shows that as the genomic sample size of the target variant reference group increases, the customized genotype imputation system 104 more accurately imputes the genotype call of the target variant. The curve 700 also shows how the customized genotype imputation system 104 can use the non-reference consistency rate and allele frequency to determine the threshold carrier rate according to the genomic sample size of the target variant reference group.
[0115] For example, to test the accuracy of the imputation of different reference groups, the researcher removes a specific target variant from the data representing the target genome sample sequenced by the sequencing device. The custom genotype imputation system 104 then imputes the genotype call of the target variant from the target genome sample based on the corresponding target variant reference group of the varying genome sample size. Figure 7 As shown, the first target variant reference group corresponding to the non-reference consistency rate curve 706d includes approximately 100 genomic samples; the second target variant reference group corresponding to the non-reference consistency rate curve 706c includes approximately 500 genomic samples; the third target variant reference group corresponding to the non-reference consistency rate curve 706b includes approximately 1,000 genomic samples; and the fourth target variant reference group corresponding to the non-reference consistency rate curve 706a includes approximately 2,500 genomic samples.
[0116] As shown in graph 700, graph 700 includes values of non-reference consistency rates along non-reference consistency rate axis 702 and values of allele frequencies along allele frequency axis 704. Specifically, non-reference consistency rate axis 702 represents the accuracy of genotype detection inference based on non-reference consistency rates from 0 to 1.0 (e.g., where 0 represents no consistency and 1.0 represents complete consistency). In graph 700, the value of such non-reference consistency rate represents the quotient of the sum of (i) the true positive rate of the target variant inferred by the sequencing system and (ii) the false positive rate, true positive rate, and false negative rate of the target variant inferred by the sequencing system, which can be expressed as TPR / FPR+TPR+FNR. In addition, allele frequency axis 704 represents the allele frequency (also called carrier rate) of the target variant from 0.00 to 0.05.
[0117] According to the non-reference consistency rate axis 702 and the allele frequency axis 704 of the curve graph 700, as the number of genomic samples represented by the target variant reference group increases, the customized genotype imputation system 104 improves the accuracy of the genotype detection imputation of the target variant. Specifically, the non-reference consistency rate curve 706d of the customized genotype imputation system 104 using the first target variant reference group representing 100 genomic samples indicates the lowest non-reference consistency rate of the target variant removed on the allele frequency of the target variant. In contrast, the non-reference consistency rate curve 706a of the customized genotype imputation system 104 using the fourth target variant reference group representing 2,500 genomic samples indicates the highest non-reference consistency rate of the target variant removed on the allele frequency of the target variant. In fact, for each of the non-reference consistency rate curve 706a, the non-reference consistency rate curve 706b and the non-reference consistency rate curve 706c, the non-reference consistency rate increases with the allele frequency and then stabilizes at the maximum consistency of the allele frequency of about 0.02.
[0118] Therefore, in some embodiments, the customized genotype imputation system 104 can accurately impute the genotype call of the target variant that exhibits at least 2% threshold carrier rate by using the target variant reference group representing 500 or more genomic samples. In fact, as shown in the non-reference consistency rate curve 706a, the customized genotype imputation system 104 can accurately impute the genotype call of the relatively less common target variant (e.g., with a carrier rate of 2% or less) by using the target variant reference group including 2,500 genomic samples. In addition, in some embodiments, the customized genotype imputation system 104 can accurately impute the genotype call of the target variant that exhibits at least 5% threshold carrier rate by using the target variant reference group representing about 100 or more genomic samples. In fact, as shown in the non-reference consistency rate curve 706d, the customized genotype imputation system 104 can accurately impute the genotype call of the relatively more common target variant (e.g., with a carrier rate of 5% or less) by using the target variant reference group representing 100 genomic samples.
[0119] As described above, the custom genotype imputation system 104 can also utilize a target variant reference set. According to one or more embodiments, Figure 8 A customized genotype imputation system 104 is shown that utilizes a target variant reference set to impute a genotype call indicating the presence or absence of a target variant within a target genomic sample. As an overview, the customized genotype imputation system 104 (i) identifies nucleotide reads of a target genomic sample, (ii) accesses a target variant reference set that includes indications of target variants within phased alleles of target variant positions of genomic samples of different haplotypes, and (iii) imputes a genotype call of a target variant within the target genomic sample based on comparing the alleles of the haplotype represented by the target variant reference set to the nucleotide reads of the target genomic sample.
[0120] like Figure 8 As shown, for example, the custom genotype imputation system 104 performs an action 802 of identifying nucleotide reads of a target genome sample. In some cases, for example, the custom genotype imputation system 104 receives data representing nucleotide reads of a genome sample that has been sequenced by a sequencing device. Such data of nucleotide reads include sequences of nucleobase calls determined by the sequencing device. After receiving the read data, the custom genotype imputation system 104 may compare the nucleotide reads to a reference genome. Based on the aligned nucleotide reads, the custom genotype imputation system 104 may determine one or more nucleobase calls of the genome coordinates and genome regions of the target genome sample relative to the reference genome.
[0121] like Figure 8As further shown, the custom genotype imputation system 104 performs an act 806 of imputing a genotype call of the target variant based on comparing the target variant reference set and the nucleotide reads. To illustrate, in one or more embodiments, the custom genotype imputation system 104 accesses the target variant reference set 808, such as by accessing a VCF stored locally or on one or more client devices within the computing system 100. In one or more embodiments, the custom genotype imputation system 104 provides and / or receives the target variant reference set 808 over a network.
[0122] like Figure 8 As shown, the target variant reference group 808 includes filled black circles indicating target variants within the target variant positions of the phased alleles of genomic samples 810a, genomic samples 810b, and genomic samples 810c representing different haplotypes. The target variant reference group 808 also includes hollow or open circles indicating marker variants within the phased alleles of genomic samples 810a to genomic samples 810c. As depicted, the phased alleles of genomic samples 810a to genomic samples 810c include different patterns indicating different alleles corresponding to different haplotypes. Similarly, Figure 8 The alleles of the target genomic sample 812 are shown including various patterns representing different alleles.
[0123] The custom genotype imputation system 104 imputes genotype calls for the target genomic sample 812 based on a comparison of (i) a subset of nucleotide reads of the target genomic sample 812 corresponding to the target genomic region of the target variant and (ii) alleles of genomic samples 810a-810c within the target variant reference set 808. More specifically, in some embodiments, the custom genotype imputation system 104 imputes genotype calls for genomic coordinates corresponding to the target genomic region based on marker variants surrounding or flanking the target genomic region of the target variant.
[0124] like Figure 8As shown, in one or more embodiments, action 806 also includes an action 814 of identifying SNPs within the nucleotide reads of the target genomic sample. More specifically, in one or more embodiments, the customized genotype inference system 104 compares marker variants surrounding the target genomic region on the target genomic sample 812 with marker variants on genomic samples 810a to genomic samples 810c included in the target variant reference group 808. In fact, in one or more embodiments, the customized genotype inference system 104 identifies marker variants within a threshold number of nucleobases from the target variant. For example, in some cases, the customized genotype inference system 104 identifies marker variants within a threshold number of nucleobases (e.g., 50 base pairs, 200 base pairs, 500 base pairs) upstream of the target genomic region and / or within a threshold number of nucleobases (e.g., 50 base pairs, 200 base pairs, 500 base pairs) downstream of the target genomic region. As described above, Figure 8 Marker variant indications of marker variants (eg, SNPs) are depicted as hollow or open circles within the phased alleles of genomic samples 810a to genomic samples 810c and target genomic sample 812.
[0125] To illustrate the comparison of marker variants, the custom genotype imputation system 104 can determine SNPs in the genomic coordinates surrounding or flanking the target genomic region on the target genomic sample 812 and SNPs in the genomic coordinates surrounding or flanking the target genomic region on the genomic samples 810a to genomic samples 810c in the target variant reference group 808. Based on the SNPs (or other marker variants) shared between the haplotypes of the target genomic sample 812 and the haplotypes of the genomic samples 810a to genomic samples 810c in the target variant reference group 808, the custom genotype imputation system 104 statistically infers which nucleobases or which alleles are more likely to be present in the target genomic region on the target genomic sample 812.
[0126] Also like Figure 8 As shown, in some embodiments, the action 806 of imputing genotype calls includes an action 816 of determining phased alleles of the target genomic sample 812. To illustrate, in one or more embodiments, the custom genotype imputation system 104 phases the nucleotide reads of the target genomic sample 812 based on marker variants (e.g., SNPs) in the nucleotide reads of the target genomic sample 812 and marker variants in the genomic samples 810a to genomic samples 810c. By comparing the marker variants and phasing the nucleotide reads relative to the haplotypes in the target variant reference group 808, the custom genotype imputation system 104 identifies the alleles of the target genomic sample 812 in the target genomic region that are also present in the maternal haplotype and the paternal haplotype of the genomic samples 810a to genomic samples 810c.
[0127] As shown by the different patterns indicating different alleles in the target variant reference group 808, for example, the alleles of the target genomic sample 812 include the same marker variant as the alleles of the genomic sample 810c. Because the custom genotype imputation system 104 can identify the common alleles between the target genomic sample 812 and one or more haplotypes of the genomic samples 810a to genomic samples 810c, and identify the target variant indications within the target variant positions of the genomic samples 810a to genomic samples 810c of the target variant reference group 808, the custom genotype imputation system 104 can generate a phased genotype call indicating the presence or absence of the target variant on a specific allele within the target genomic sample 812. As shown by the filled black circles representing the target variant indications in the target variant reference group 808, the custom genotype imputation system 104 can statistically infer that a specific allele of the target genomic sample 812 includes the target variant because the corresponding allele of the genomic sample 810c includes the target variant indication in the target variant position. In practice, by applying the haplotype phasing model and the genotype inference model to the target variant reference group 808, the customized genotype inference system 104 can determine a phased genotype call that indicates the presence or absence of the target variant at the allele of the target genomic sample 812 corresponding to the maternal haplotype or the paternal haplotype represented in the target variant reference group 808.
[0128] As just noted, in one or more embodiments, the custom genotype imputation system 104 phases the nucleotide reads from the target genome sample 812 using a haplotype phasing model. In one or more embodiments, the custom genotype imputation system 104 uses the segmented haplotype estimation and imputation tool (SHAPEIT) to estimate haplotypes from genotype data, including nucleotide reads of the target genome sample 812 and genomic sequences of genome samples 810a to genomic samples 810c in the target variant reference group 808. To illustrate, in one or more embodiments, the custom genotype imputation system 104 uses the SHAPEIT algorithm to perform a positional Burrow Wheeler transformation (PBWT) to effectively select a group of related haplotypes for phasing the nucleotide reads of the target genome sample 812. Therefore, the custom genotype imputation system 104 can pre-process and extract phasing information from the group of related haplotypes. In one or more embodiments, the custom genotype imputation system 104 may also utilize the haplotype framework or parental haplotype data to phase the nucleotide reads of the target genomic sample 812. Thus, the custom genotype imputation system 104 may utilize the phasing information from the set of related haplotypes and optionally utilize the haplotype framework or parental haplotype data to write a VCF or BCF file that phases the target genomic sample 812. In one or more embodiments, the custom genotype imputation system 104 utilizes HTSlib to write the VCF or BCF file.
[0129] In some embodiments, for example, the custom genotype imputation system 104 uses SHAPEIT to phase haplotypes as described in Olivier Delaneau, Jean-Francois Zagury et al., Scalable and Integrative Haplotype Estimation, Nat. Comm. (2019), which is hereby incorporated by reference in its entirety.
[0130] As also described above, in one or more embodiments, the customized genotype imputation system 104 applies a genotype imputation model such as a hidden Markov model (HMM)-based genotype imputation model to impute the genotype call corresponding to the target region of the target variant. To illustrate, in some embodiments, the customized genotype imputation system 104 may utilize an HMM-based genotype imputation model to identify the relevant haplotypes of genomic samples 810a to genomic samples 810c from the target variant reference group 808. More specifically, the customized genotype imputation system 104 may utilize an HMM-based genotype imputation model to (i) compare the marker variants corresponding to the target genomic region of the target genomic sample 812 with the marker variants in the haplotypes of the target genomic region within the genomic samples 810a to genomic samples 810c, and (ii) identify the possible haplotypes corresponding to the target genomic region present in the target genomic sample 812.
[0131] In one or more embodiments, the customized genotype imputation system 104 utilizes a genotype likelihood imputation and phasing method (GLIMPSE) as a genotype imputation model, as described in Simone Rubinacci et al., "Efficient Phasing and Imputation of Low-coverage Sequencing Data Using Large Reference Panels", 53 Nature Genetics 120-126 (2021), which is hereby incorporated by reference in its entirety. More specifically, in some embodiments, the customized genotype imputation system 104 utilizes GLIMPSE to determine the posterior genotype likelihood of the target genomic region corresponding to the target variant of the target genomic sample 812. In fact, in some embodiments, the customized genotype imputation system 104 executes SHAPEIT to phase the nucleotide reads from the target genomic sample before executing GLIMPSE based on the target variant reference group to infer the genotype call of the target variant.
[0132] As described above, in one or more embodiments, the customized genotype imputation system 104 generates a target variant reference group, which includes one or more target genomic regions (or genomic regions of interest) corresponding to the target variant and does not include other genomic coordinates or genomic regions. For illustration, in some embodiments, the customized genotype imputation system 104 limits the target variant reference group to data including haplotypes of genomic samples corresponding to one or more target genomic regions corresponding to the target variant, but does not include data representing haplotypes outside the one or more target genomic regions. In fact, in one or more embodiments, the customized genotype imputation system 104 includes data representing haplotypes of genomic samples from multiple target genomic regions (including different chromosomes) in the target variant reference group corresponding to multiple target variants. For example, the customized genotype imputation system 104 can generate a target variant reference group, which includes data representing different haplotypes of target variants of the CYP2D6 gene corresponding to the target genomic region (e.g., chr4:35149660-47004037). In some cases, the same target variant reference set includes data representing different haplotypes corresponding to additional target variants of the RFC1 gene at additional target genomic regions (e.g., chr22:37149660-54004037).
[0133] In fact, in one or more embodiments, the customized genotype imputation system 104 inputs data of such a target variant reference set only for the target genomic region into the genotype imputation model (e.g., GLIMPSE). By reducing or eliminating unnecessary genomic regions and using a target variant reference set that includes data limited to one or more target genomic regions, the customized genotype imputation system 104 uses less memory to store the target variant reference set and speeds up the computer processing time for executing the genotype imputation model to impute the genotype call of the target variant.
[0134] As an alternative to GLIMPSE, in some embodiments, the custom genotype imputation system 104 uses a different HMM-based genotype imputation model to impute haplotypes, such as the model described in Genetic Variants Predictive of Cancer Risk, WO 2013 / 035 / 114A1 (published on March 14, 2013) or by A. Kong et al., Detection of Sharing by Descent, Long-Range Phasing and Haplotype Imputation, Nat. Genet. 40, 1068-75 (2008), the disclosures of which are incorporated herein by reference in their entirety. Additionally or alternatively, the custom genotype imputation system 104 uses other available software such as BEAGLE, MACH or IMPUTE to impute genotype calls.
[0135] like Figure 8 As further shown, the custom genotype imputation system 104 can optionally perform an action 818 of generating a prediction of whether the target genomic sample includes the target variant. To illustrate, in one or more embodiments, the custom genotype imputation system 104 can use the determined genotype call to generate a prediction of whether the target genomic sample includes a pathogenic variant at an allele present on the maternal haplotype or the paternal haplotype. As described below with respect to Fig. 9 As discussed, the custom genotype imputation system 104 can provide such predictions to a client device via a graphical user interface.
[0136] In some embodiments, for example, the custom genotype imputation system 104 can generate a prediction using a genetic pattern associated with a disorder or disease corresponding to a target variant. To illustrate, the custom genotype imputation system 104 can determine whether the disorder associated with the target variant is autosomal recessive, autosomal dominant, X chromosome linkage, Y chromosome linkage, codominant or multiple genetic patterns. More specifically, the custom genotype imputation system 104 compares the genetic pattern with the genotype detection to generate a prediction. In some embodiments, the prediction indicates whether the target genome sample is a carrier of a target variant at a specific allele, a case of a target variant at two alleles, or is not affected by the target variant at any allele.
[0137] After determining the imputed genotype calls, in one or more embodiments, the custom genotype imputation system 104 provides information about such imputed genotype calls for one or more target variants via a graphical user interface. According to one or more embodiments, Fig. 9A client device 900 is shown presenting a graphical user interface 901 including information about the imputed genotype calls for a target variant. Fig. 9 The graphical user interface 901 displayed when the client device 900 implements the computer executable instructions of the customized genotype estimation system 104 is shown, but the present disclosure does not repeatedly mention the computer executable instructions that cause the client device 900 to perform specific actions of the customized genotype estimation system 104, but instead describes the client device 900 or the customized genotype estimation system 104 that performs those actions in the following paragraphs.
[0138] like Fig. 9 As shown, for example, client device 900 provides data in target variant column 902, gene column 904 and carrier rate column 906. For illustration, target variant column 902 includes data identifying target variant and corresponding prediction. More specifically, client device 900 presents the genomic coordinates of target variant and the prediction of whether the target genome sample includes target variant (e.g., pathogenic variant). For illustration, in one or more embodiments, custom genotype inference system 104 provides prediction of whether there is pathogenic variant in target genome sample at allele on one or both of maternal haplotype and paternal haplotype to client device 900.
[0139] Thus, based on the inferred genotype calls, the client device 900 can present a prediction as to whether the target genomic sample is affected by one or more target variants. Fig. 9 As shown, for example, the client device 900 presents a target variant column 902 that includes a "Prediction: Case" for a first target variant within the target genomic sample at the genomic coordinates "chr4:39,287,456-39..." As shown in "Prediction: Case", the customized genotype inference system 104 predicts that the target genomic sample includes the first target variant of the RFC1 gene on both alleles. Therefore, in some cases, the prediction indicates a potential phenotype of the target genomic sample on the spectrum of cerebellar ataxia, neuropathy, vestibular dysreflexia syndrome (CANVAS). As shown in "Prediction: Case", the customized genotype inference system 104 predicts that the target genomic sample includes the first target variant of the RFC1 gene on both alleles. Fig. 9 As further shown, the client device 900 presents a target variant column 902 that includes a "Prediction: Carrier" for a second target variant within the target genome sample at the genomic coordinates "chr22:42,126,499-42..." As indicated by "Prediction: Carrier", in some cases, the customized genotype imputation system 104 predicts that the target genome sample includes the second target variant of the CYP2D6 gene on one allele. Therefore, the prediction indicates that the target genome sample carries a variant that is genetically indicative of neuroleptic malignant syndrome.
[0140] like Fig. 9As further shown, the client device 900 presents annotations corresponding to the gene and carrier rate of the target variant and the corresponding prediction of the gene and carrier rate. For example, the client device 900 presents a gene column 904, which includes the predicted "RFC1" and "CYP2D6" in the target variant column 902 corresponding to the first target variant and the second target variant, respectively. In addition to specific gene identification, the client device 900 presents the carrier rate in the carrier rate column 906. More specifically, the client device 900 presents a carrier rate of 0.7% to 4% for the first target variant on the RFC1 gene and a carrier rate of 5% for the second target variant on the CYP2D6 gene. In some embodiments, the carrier rate represents the frequency of the target variant from the genomic sample database or from the metadata corresponding to the target variant reference group. By providing predictions, genomic coordinates, genes and carrier rates, the customized genotype inference system 104 provides key information indicating the variant detection of a specific gene to clinicians, subjects or other people.
[0141] Figures 1 to 9 , corresponding text and examples provide many different methods, systems, devices and non-transitory computer-readable media for customizing the genotype estimation system 104. In addition to the foregoing, one or more embodiments may also be described in terms of a flowchart including actions for achieving a particular result, such as Figure 10 to Figure 11 shown. Figure 10 to Figure 11 Can be performed with more or less actions.In addition, these actions can be performed in different orders.In addition, the actions described herein can be repeated or performed in parallel with each other or in parallel with different examples of the same or similar actions.
[0142] As mentioned, Fig.10 1000 for generating a reference set of target variants according to one or more embodiments. Fig.10 The actions according to one embodiment are illustrated, but alternative embodiments may omit, add, reorder, and / or modify Fig.10 Any action shown. Fig.10 The actions of may be performed as part of a method. Alternatively, the non-transitory computer readable medium may include a computer program that, when executed by one or more processors, causes a computing device or system to perform Fig.10 In some embodiments, the system may execute Fig.10 action.
[0143] like Fig.10As shown, the series of actions 1000 include an action 1002 for generating a reference group, which includes marker variant indications corresponding to genomic samples of different haplotypes. Specifically, action 1002 may include generating a reference group, which includes marker variant indications of marker variants at genomic coordinates corresponding to genomic samples of different haplotypes. Specifically, in some cases, at least one target variant position includes a target variant position indicated by a target variant of a biallelic target variant. In addition, in one or more embodiments, in some cases, at least one target variant position includes multiple target variant positions indicated by a target variant of a multi-allelic target variant.
[0144] Furthermore, in one or more embodiments, in some cases, the marker variant comprises a single nucleotide polymorphism (SNP).
[0145] like Fig.10 As shown, the series of actions 1000 include an action 1004 for adding the target variant position to a reference group indicating the presence or absence of the target variant in the genomic sample. Specifically, action 1004 may include adding at least one target variant position to a reference group indicating the presence or absence of the target variant in the genomic sample. Specifically, in some cases, the target variant includes a repeat sequence amplification. In addition, in one or more embodiments, action 1004 includes, wherein the target variant includes a deletion, insertion, duplication, inversion, translocation or copy number variation (CNV) propagated within the population. Action 1004 may also include, wherein the target variant meets one or more of a threshold carrier rate, a threshold linkage disequilibrium (LD) or a threshold mutation rate for a specific marker variant.
[0146] In addition, in one or more embodiments, the target variants include variants of the replication factor C subunit 1 (RFC1) gene, the cytochrome P450 family 2 subfamily D member 6 (CYP2D6) gene, the cytochrome P450 family 2 subfamily B member 6 (CYP2B6) gene, the cytochrome P450 family 21 subfamily A member 2 (CYP21A2) gene, the survival of motor neuron 1 (SMN1) gene, the survival of motor neuron 2 (SMN2) gene, the glucocerebrosidase beta (GBA) gene, the blood group Rh (CE) (RHCE) gene, the lipoprotein (A) (LPA) gene, the fragile X mental retardation 1 (FMR1) gene, the hexosaminidase subunit alpha (HEXA) gene, the hemoglobin subunit alpha 1 (HBA1) gene, the hemoglobin subunit alpha 2 (HBA2) gene, or the hemoglobin subunit beta (HBB) gene.
[0147] like Fig.10As shown, the series of actions 1000 include an action 1006 for phasing the alleles of the genomic sample based on the marker variant to determine the presence or absence of the target variant in the corresponding allele. Specifically, action 1006 may include phasing the alleles of the genomic sample based on the marker variant to determine the presence or absence of the target variant in the corresponding allele present in the maternal haplotype and the paternal haplotype. Specifically, in some cases, phasing the alleles of the genomic sample includes phasing the heterozygous alleles of a subset of the genomic sample.
[0148] like Fig.10 As shown, the series of actions 1000 include an action 1008 for generating a target variant reference group including a target variant indication. Specifically, action 1008 may include generating a target variant reference group, which includes a target variant indication within at least one target variant position of a phased allele of a genomic sample. Specifically, in some cases, generating a reference group includes generating a phased reference group, which includes a marker variant indication of a marker variant phased according to the maternal haplotype and the paternal haplotype of the genomic sample. In addition, in one or more embodiments, in some cases, genomic samples of different haplotypes include genomic samples of different haplotypes that exhibit genetic diversity. In some cases, the target variant reference group includes a marker variant indication of a marker variant within the target genomic region of the target variant and does not include an additional marker variant indication of an additional marker variant outside the target genomic region.
[0149] in addition, Fig.11 1100 is a flow chart showing a series of actions 1100 for inferring genotype calls using a reference set of target variants according to one or more embodiments. Fig.11 Actions according to one embodiment are shown, but alternative embodiments may omit, add, reorder, and / or modify Fig.11 Any action shown. Fig.11 The actions of may be performed as part of a method. Alternatively, the non-transitory computer readable medium may include a computer program that, when executed by one or more processors, causes a computing device or system to perform Fig.11 In some embodiments, the system may execute Fig.11 action.
[0150] like Fig.11 As shown, the series of actions 1100 includes an action 1102 of identifying nucleotide reads of a target genomic sample. Specifically, action 1102 may include identifying nucleotide reads corresponding to the target genomic sample.
[0151] like Fig.11As shown, the series of actions 1100 include an action 1104 for accessing a target variant reference group including a target variant indication. Specifically, action 1104 may include accessing a target variant reference group, which includes a target variant indication within at least one target variant position of a phased allele of a genomic sample of different haplotypes. Specifically, in some cases, the target variant indication indicates the presence or absence of a target variant in at least one target variant position of a phased allele of a genomic sample. In some cases, the target variant reference group includes a marker variant indication of a marker variant within a target genomic region of the target variant and does not include an additional marker variant indication of an additional marker variant outside the target genomic region.
[0152] like Fig.11 As shown, the series of actions 1100 include an action 1106 for inferring the genotype call of the target variant within the target genome sample based on a comparison of the target variant reference group with the nucleotide reads. Specifically, action 1106 may include inferring the genotype call of the target variant within the target genome sample based on a comparison of the target variant reference group with the nucleotide reads corresponding to the target genome sample. Specifically, action 1106 may include determining the phased alleles of the target genome sample based on a comparison of the target variant reference group with the nucleotide reads corresponding to the target genome sample, and inferring the genotype call by inferring the phased genotype call of the target variant within the target genome sample based on the phased alleles of the target genome sample.
[0153] Additionally, in one or more embodiments, action 1106 includes inferring a genotype call of the target variant by generating a prediction of whether the target genomic sample includes the target variant. Additionally, in some embodiments, generating the prediction includes predicting whether the target genomic sample includes a pathogenic variant at an allele present on the maternal haplotype or the paternal haplotype.
[0154] Action 1106 may also include inferring genotype calls by identifying one or more single nucleotide polymorphisms (SNPs) as one or more marker variants within a target variant reference set of target variants within a nucleotide read corresponding to the target genomic sample, and also determining the genotype calls based on the one or more SNPs within the nucleotide reads. In addition, action 1106 may include inferring the genotype calls of the target variant by inferring the genotype calls of the repeat sequence amplification. In addition, action 1106 may include inferring the genotype calls of the target variant using a genotype inference model.
[0155] Methods described herein can be used in combination with multiple nucleic acid sequencing techniques. Particularly suitable techniques are those in which nucleic acids are attached to fixed positions in an array so that their relative positions do not change and in which the array is repeatedly imaged. Embodiments in which images are obtained in different color channels (e.g., matching different markers for distinguishing a nucleotide base type from another nucleotide base type) are particularly suitable. In some embodiments, the process of determining the nucleotide sequence of a target nucleic acid (i.e., nucleic acid polymer) can be an automated process. Preferred embodiments include sequencing by synthesis (SBS) technology.
[0156] SBS techniques generally include enzymatic extension of nascent nucleic acid chains by repeated addition of nucleotides to the template strand. In traditional SBS methods, a single nucleotide monomer can be provided to the target nucleotide in the presence of a polymerase in each delivery. However, in the methods described herein, more than one type of nucleotide monomer can be provided to the target nucleic acid in the presence of a polymerase in the delivery.
[0157] SBS can utilize nucleotide monomers with terminator parts or lack nucleotide monomers of any terminator parts.The method utilizing the nucleotide monomers lacking terminator includes for example pyrophosphate sequencing and the sequencing of nucleotides using gamma-phosphate labeling, as described in further detail below.In the method using the nucleotide monomers lacking terminator, the number of nucleotides added in each cycle is usually variable, and the number depends on the mode of template sequence and nucleotide delivery.For utilizing the SBS technology of the nucleotide monomers with terminator parts, terminator can be effectively irreversible under the sequencing conditions used, such as the situation of traditional Sanger sequencing utilizing dideoxynucleotides, or terminator can be reversible, such as the situation of the sequencing method developed by Solexa (now Illumina, Inc.).
[0158] The SBS technique can utilize nucleotide monomers with a labeling portion or nucleotide monomers lacking a labeling portion. Thus, incorporation events can be detected based on the following items: properties of the label, such as the fluorescence of the label; properties of the nucleotide monomer, such as molecular weight or charge; byproducts of the incorporated nucleotide, such as the release of pyrophosphate; and the like. In embodiments where two or more different nucleotides are present in the sequencing reagent, the different nucleotides may be distinguishable from each other, or alternatively, the two or more different labels may be indistinguishable under the detection technology used. For example, different nucleotides present in the sequencing reagent may have different labels, and they may be distinguished using appropriate optical devices, as exemplified by the sequencing method developed by Solexa (now Illumina, Inc.).
[0159] Preferred embodiments include pyrophosphate sequencing technology. Pyrophosphate sequencing detects the release of inorganic pyrophosphate (PPi) when a specific nucleotide is incorporated into a nascent chain (Ronaghi, M., Karamohamed, S., Pettersson, B., Uhlen, M., and Nyren, P. (1996), "Real-time DNA sequencing using detection of pyrophosphate release.", Analytical Biochemistry 242 (1), 84-9; Ronaghi, M. (2001), "Pyrosequencing sheds light on DNA sequencing.", Genome Res. 11 (1), 3-11; Ronaghi, M., Uhlen, M., and Nyren, P. (1998), "A sequencing method based on real-time pyrophosphate.", Science 281 (5375), 363; U.S. Pat. No. 6,210,991; U.S. Pat. No. 6,258,568 and U.S. Pat. No. 6,274,320, the disclosures of which are incorporated herein by reference in their entirety). In pyrophosphate sequencing, the released PPi can be detected by being immediately converted into ATP by adenosine triphosphate (ATP) sulfurylase, and the level of ATP generated is detected by photons generated by luciferase. The nucleic acid to be sequenced can be attached to a feature in an array, and the array can be imaged to capture the chemiluminescent signal generated by the incorporation of nucleotides at the feature of the array. The image can be obtained after the array is treated with a specific nucleotide type (e.g., A, T, C or G). The images obtained after adding each nucleotide type will differ in which features in the array are detected. These differences in the image reflect the different sequence contents of the features on the array. However, the relative position of each feature will remain unchanged in the image. The images can be stored, processed and analyzed using the methods described herein. For example, images obtained after treating the array with each different nucleotide type can be processed in the same manner as exemplified herein for images obtained from different detection channels for a reversible terminator-based sequencing method.
[0160] In another exemplary type of SBS, cycle sequencing is accomplished by stepwise addition of reversible terminator nucleotides comprising, for example, cleavable or photobleachable dye labels, as described in, for example, WO 04 / 018497 and U.S. Pat. No. 7,057,026, the disclosures of which are incorporated herein by reference. The method is commercialized by Solexa (now Illumina Inc.) and is also described in WO 91 / 06678 and WO 07 / 123,844, the disclosures of each of which are incorporated herein by reference. The availability of fluorescently labeled terminators, in which not only termination can be reversed but also the fluorescent label can be cleaved, facilitates efficient cyclic reversible termination (CRT) sequencing. Polymerases can also be co-engineered to efficiently incorporate and extend from these modified nucleotides.
[0161] Preferably, in the sequencing embodiment based on reversible terminator, the label does not substantially inhibit extension under SBS reaction conditions. However, the detection label can be removable, such as removed by cleavage or degradation. Images can be captured after the label is incorporated into the arrayed nucleic acid feature. In a specific embodiment, each cycle involves four different nucleotide types being delivered to the array simultaneously, and each nucleotide type has a label that is spectrally different. Four images can then be obtained, each image using a detection channel that is selective to one label in the four different labels. Alternatively, different nucleotide types can be added sequentially, and the image of the array can be obtained between each addition step. In such embodiments, each image will show the nucleic acid feature that has been incorporated with a specific type of nucleotide. Due to the different sequence content of each feature, different feature portions are present or absent in different images. However, the relative position of the feature portion will remain unchanged in the image. The image obtained by such reversible terminator-SBS method can be stored, processed and analyzed as described herein. After the image capture step, the label can be removed and the reversible terminator portion can be removed for subsequent cycles of nucleotide addition and detection. Removing labels after they have been detected in a particular cycle and before subsequent cycles can provide the advantage of reducing background signal and crosstalk between cycles. Examples of useful labeling and removal methods are set forth below.
[0162] In a specific embodiment, some or all of the nucleotide monomers may include a reversible terminator. In such embodiments, the reversible terminator / cleavable fluorophore may include a fluorophore (Metzker, Genome Res. 15: 1767-1776 (2005), which is incorporated herein by reference) connected to a ribose moiety via a 3' ester bond. Other methods have separated terminator chemistry from the cleavage of a fluorescent label (Ruparel et al., Proc Natl Acad Sci USA 102: 5932-7 (2005), which is incorporated herein by reference in its entirety). Ruparel et al. describe the development of reversible terminators that use small 3' allyl groups to block extension, but can be easily deblocked by a short treatment with a palladium catalyst. The fluorophore is attached to the base via a photocleavable linker that can be easily cleaved by exposure to long wavelength ultraviolet light for 30 seconds. Therefore, disulfide reduction or photocleavage can be used as a cleavable linker. Another method of reversible termination is to use natural termination, which occurs after a bulky dye is placed on a dNTP. The presence of a charged bulky dye on a dNTP can act as an efficient terminator by steric hindrance and / or electrostatic hindrance. Unless the dye is removed, the presence of an incorporation event prevents further incorporation. The cracking of the dye removes the fluorophore and effectively reverses termination. The example of modified nucleotides is also described in U.S. Patent No. 7,427,673 and U.S. Patent No. 7,057,026, the disclosure of which is incorporated herein by reference in its entirety.
[0163] Additional exemplary SBS systems and methods that may be utilized with the methods and systems described herein are described in U.S. Patent Application Publication No. 2007 / 0166705, U.S. Patent Application Publication No. 2006 / 0188901, U.S. Patent No. 7,057,026, U.S. Patent Application Publication No. 2006 / 0240439, U.S. Patent Application Publication No. 2006 / 0281109, PCT Publication No. WO05 / 065814, U.S. Patent Application Publication No. 2005 / 0100900, PCT Publication No. WO 06 / 064199, PCT Publication No. WO07 / 010,251, U.S. Patent Application Publication No. 2012 / 0270305, and U.S. Patent Application Publication No. 2013 / 0260372, the disclosures of which are incorporated herein by reference in their entireties.
[0164] Some embodiments can use the detection of four different nucleotides using less than four different marks.For example, the method and system described in the material of the U.S. Patent Application Publication No. 2013 / 0079232 incorporated can be used to perform SBS.As the first example, a pair of nucleotide types can be detected at the same wavelength, but based on the intensity difference of a member in the pair relative to another member, or based on a member in the pair causing a change (for example, by chemical modification, photochemical modification or physical modification) that a signal that is obvious compared with the signal of another member of the pair detected appears or disappears.As the second example, three of the four different nucleotide types can be detected under specific conditions, and the fourth nucleotide type lacks a mark (for example, the minimum detection caused by background fluorescence, etc.) that can be detected under those conditions or detected minimally under those conditions.The first three nucleotide types can be determined to be incorporated into nucleic acid based on the existence of its corresponding signal, and the fourth nucleotide type can be determined to be incorporated into nucleic acid based on the absence of any signal or the minimum detection of any signal.As the third example, a nucleotide type can include a mark detected in two different channels, and other nucleotide types are detected in no more than one channel. The three exemplary configurations described above are not considered mutually exclusive and can be used in various combinations. An exemplary embodiment combining all three examples is a fluorescence-based SBS method that uses a first nucleotide type detected in a first channel (e.g., dATP with a label detected in the first channel when excited by a first excitation wavelength), a second nucleotide type detected in a second channel (e.g., dCTP with a label detected in the second channel when excited by a second excitation wavelength), a third nucleotide type detected in both the first channel and the second channel (e.g., dTTP with at least one label detected in both channels when excited by the first excitation wavelength and / or the second excitation wavelength), and a fourth nucleotide type that lacks a label detected or minimally detected in either channel (e.g., dGTP without a label).
[0165] In addition, as described in the materials of incorporated U.S. Patent Application Publication No. 2013 / 0079232, a single channel can be used to obtain sequencing data. In such so-called single dye sequencing methods, a first nucleotide type is marked, but the mark is removed after the first image is generated, and a second nucleotide type is marked only after the first image is generated. A third nucleotide type retains its mark in both the first image and the second image, and a fourth nucleotide type remains unmarked in both images.
[0166] Some embodiments can utilize sequencing technology while connecting. Such technology utilizes DNA ligase to incorporate oligonucleotides and recognize the incorporation of such oligonucleotides. Oligonucleotides generally have different labels related to the identity of specific nucleotides in the sequence of oligonucleotide hybridization. As with other SBS methods, images can be obtained after the array of nucleic acid features is treated with labeled sequencing reagents. Each image will show the nucleic acid features of the labeling of a specific type. Due to the different sequence content of each feature, different features are present or absent in different images, but the relative position of the features will remain unchanged in the image. The images obtained by the sequencing method based on connection can be stored, processed and analyzed as described herein. Exemplary SBS systems and methods that can be used with the methods and systems described herein are described in U.S. Patent No. 6,1069,488, U.S. Patent No. 6,172,218 and U.S. Patent No. 6,306,597, and the disclosures of these patents are incorporated herein by reference in their entirety.
[0167] Some embodiments may utilize nanopore sequencing (Deamer, DW and Akeson, M., "Nanopores and nucleic acids: prospects for ultrarapid sequencing.", Trends Biotechnol. 18, 147-151 (2000); Deamer, D. and D. Branton, "Characterization of nucleic acids by nanopore analysis.", Acc. Chem. Res. 35: 917-925 (2002); Li, J., M. Gershow, D. Stein, E. Brandin and JA Golovchenko, "DNA molecules and configurations in a solid-state nanopore microscope", Nat. Mater., 2: 611-615 (2003), the disclosures of which are incorporated herein by reference in their entirety). In such embodiments, the target nucleic acid passes through the nanopore. The nanopore may be a synthetic pore or a biological membrane protein, such as α-hemolysin. As the target nucleic acid passes through the nanopore, each base pair can be identified by measuring the fluctuations in the conductivity of the pore. (U.S. Pat. No. 7,001,892; Soni, GV and Meller, "A. Progress toward ultrafast DNA sequencing using solid-state nanopores.", Clin. Chem. 53, 1996-2001 (2007); Healy, K., "Nanopore-based single-molecule DNA analysis.", Nanomed., 2, 459-481 (2007); Cockroft, SL, Chu, J., Amorin, M. and Ghadiri, MR, "A single-molecule nanopore device detects DNA polymerase activity with single-nucleotide resolution.", J. Am. Chem. Soc. 130, 818-820 (2008), the disclosures of which are incorporated herein by reference in their entirety). The data obtained from nanopore sequencing can be stored, processed and analyzed as described herein. In particular, according to the exemplary processing of optical images and other images described herein, the data may be processed as if it were an image.
[0168] Some embodiments may utilize methods involving real-time monitoring of DNA polymerase activity. Nucleotide incorporation may be detected by fluorescence resonance energy transfer (FRET) interactions between a polymerase carrying a fluorophore and a γ-phosphate labeled nucleotide, as described, for example, in U.S. Pat. No. 7,329,492 and U.S. Pat. No. 7,211,414 (each of which is incorporated herein by reference), or may be detected by zero-mode waveguides, as described, for example, in U.S. Pat. No. 7,315,019 (which is incorporated herein by reference), and may be detected by fluorescent nucleotide analogs and engineered polymerases, as described, for example, in U.S. Pat. No. 7,405,281 and U.S. Patent Application Publication No. 2008 / 0108082 (each of which is incorporated herein by reference). Illumination can be limited to a volume of the order of magnitude surrounding the surface-tethered polymerase, so that the incorporation of fluorescently labeled nucleotides can be observed under low background (Levene, MJ et al., "Zero-mode waveguides for single-molecule analysis at high concentrations.", Science 299, 682-686 (2003); Lundquist, PM et al., "Parallel confocal detection of single molecules in real time.", Opt. Lett. 33, 1026-1028 (2008); Korlach, J. et al., "Selective aluminum passivation for targeted immobilization of single DNA polymerase molecules in zero-mode waveguide nano structures.", Proc. Natl. Acad. Sci. USA 105, 1176-1181 (2008), the disclosures of which are incorporated herein by reference in their entirety). Images obtained by such methods can be stored, processed, and analyzed as described herein.
[0169] Some SBS embodiments include detecting the proton released when nucleotides are incorporated into extension products. For example, sequencing based on the detection of releasing protons can use the commercially available electrical detectors and related technologies from Ion Torrent company (Guilford, CT, it is a Life Technologies subsidiary) or the sequencing methods and systems described in US 2009 / 0026082A1, US2009 / 0127589 A1, US2010 / 0137143 A1 or US 2010 / 0282617A1, each of which is incorporated herein by reference. The method for amplifying target nucleic acids using kinetic exclusion set forth herein can be easily applied to substrates for detecting protons. More specifically, the method set forth herein can be used to produce amplicon clone colonies for detecting protons.
[0170] The above-mentioned SBS method can be advantageously carried out in a variety of formats so that a plurality of different target nucleic acids are manipulated simultaneously. In a specific embodiment, different target nucleic acids can be processed in a common reaction vessel or on the surface of a specific substrate. This allows to conveniently deliver sequencing reagents, remove unreacted reagents and detect incorporation events in a variety of ways. In the embodiment using the target nucleic acid of surface binding, the target nucleic acid can be an array format. In the array format, the target nucleic acid can be attached to the surface in a spatially distinguishable manner generally. The target nucleic acid can be attached by direct covalent attachment, attached to beads or other particles or attached to a polymerase or other molecules attached to the surface to combine. The array can include a single copy of the target nucleic acid at each site (also referred to as a feature portion), or multiple copies with the same sequence can be present at each site or feature portion. Multiple copies can be produced by an amplification method (such as bridge amplification or emulsion PCR as described in further detail below).
[0171] The methods described herein may use arrays having features at any of a variety of densities, including, for example, at least about 10 features / cm 2 , 100 features / cm 2 , 500 features / cm 2 , 1,000 features / cm 2 , 5,000 features / cm 2 , 10,000 features / cm 2 , 50,000 features / cm 2 , 100,000 features / cm 2 , 1,000,000 features / cm 2 , 5,000,000 features / cm 2 or higher.
[0172] The advantage of the method described herein is that they provide rapid and effective detection of multiple target nucleic acids in parallel. Therefore, the present disclosure provides an integrated system that can use technology known in the art (such as those illustrated above) to prepare and detect nucleic acids. Therefore, the integrated system of the present disclosure may include a fluid component that can deliver amplification reagents and / or sequencing reagents to one or more fixed DNA fragments, and the system includes components such as pumps, valves, reservoirs, fluid pipelines, etc. The circulation cell can be configured for and / or for detecting target nucleic acids in the integrated system. Exemplary circulation cells are described in, for example, US 2010 / 0111768A1 and U.S. Serial No. 13 / 273,666, each of which is incorporated herein by reference. As illustrated for the circulation cell, one or more fluid components of the integrated system can be used for amplification method and detection method. Taking nucleic acid sequencing embodiment as an example, one or more fluid components of the integrated system can be used for the amplification method described herein and for delivering sequencing reagents in sequencing method (such as those illustrated above). Alternatively, the integrated system may include a separate fluid system to perform amplification method and perform detection method. Examples of integrated sequencing systems that can generate amplified nucleic acids and also determine nucleic acid sequences include, but are not limited to, MiSeq TM The ELISA platform (Illumina, Inc., San Diego, CA) and the apparatus described in U.S. Ser. No. 13 / 273,666, which is incorporated herein by reference.
[0173] The above sequencing system sequences the nucleic acid polymers present in the sample received by the sequencing device. As defined herein, "sample" and its derivatives are used in their broadest sense, including any specimens, cultures, etc. suspected of containing a target. In some embodiments, the sample includes nucleic acids in DNA, RNA, PNA, LNA, chimeric or hybrid forms. The sample may include any biological, clinical, surgical, agricultural, atmospheric or aquatic animal and plant specimens containing one or more nucleic acids. The term also includes any isolated nucleic acid sample, such as genomic DNA, fresh frozen or formalin-fixed paraffin-embedded nucleic acid specimens. It is also envisioned that the source of the sample can be: a single individual, a collection of nucleic acid samples from genetically related members, a nucleic acid sample from a genetically unrelated member, a nucleic acid sample (matched therewith) from a single individual (such as a tumor sample and a normal tissue sample), or a sample from a single source containing two different forms of genetic material (such as maternal DNA and fetal DNA obtained from a maternal subject), or there is contaminating bacterial DNA in a sample containing plant or animal DNA. In some embodiments, the source of the nucleic acid material may include nucleic acids obtained from newborns, such as nucleic acids commonly used for newborn screening.
[0174] Nucleic acid samples may include high molecular weight substances, such as genomic DNA (gDNA). Samples may include low molecular weight substances, such as nucleic acid molecules obtained from FFPE samples or archived DNA samples. In another embodiment, low molecular weight substances include DNA of enzymatic fragmentation or mechanical fragmentation. Samples may include cell-free circulating DNA. In some embodiments, samples may include nucleic acid molecules obtained from biopsy tissue, tumor, scrapings, swabs, blood, mucus, urine, plasma, semen, hair, laser capture microdissection, surgical resection and other clinical or laboratory samples. In some embodiments, samples may be epidemiological samples, agricultural samples, forensic samples or pathogenic samples. In some embodiments, samples may include nucleic acid molecules obtained from animals (such as humans or mammalian sources). In another embodiment, samples may include nucleic acid molecules obtained from non-mammalian sources (such as plants, bacteria, viruses or fungi). In some embodiments, the source of nucleic acid molecules may be archived or extinct samples or species.
[0175] In addition, the methods and compositions disclosed herein can be used to amplify nucleic acid samples with low-quality nucleic acid molecules, such as degraded and / or fragmented genomic DNA from forensic samples. In one embodiment, forensic samples may include nucleic acids obtained from crime scenes, nucleic acids obtained from missing persons DNA databases, nucleic acids obtained from laboratories associated with forensic investigations, or include forensic samples obtained by law enforcement agencies, one or more military services, or any such personnel. Nucleic acid samples can be purified samples or lysates containing crude DNA, such as from oral swabs, paper, fabrics, or other substrates that can be impregnated with saliva, blood, or other body fluids. Therefore, in some embodiments, the nucleic acid sample may include a small amount of DNA (such as genomic DNA), or a fragmented portion of DNA. In some embodiments, the target sequence may be present in one or more body fluids, wherein body fluids include but are not limited to blood, sputum, plasma, semen, urine, and serum. In some embodiments, the target sequence may be obtained from the victim's hair, skin, tissue sample, autopsy, or remains. In some embodiments, nucleic acids comprising one or more target sequences may be obtained from dead animals or humans. In some embodiments, the target sequence may include a nucleic acid obtained from non-human DNA (such as microbial, plant, or insect DNA). In some embodiments, the target sequence or amplified target sequence is directed to the purpose of human identification. In some embodiments, the disclosure as a whole relates to methods for identifying the characteristics of forensic samples. In some embodiments, the disclosure as a whole relates to human identification methods using one or more target-specific primers disclosed herein or one or more target-specific primers designed using the primer design standards outlined herein. In one embodiment, a forensic sample or human identification sample containing at least one target sequence can be amplified using any one or more target-specific primers disclosed herein or using the primer standards outlined herein.
[0176] The components of the customized genotype imputation system 104 may include software, hardware, or both. For example, the components of the customized genotype imputation system 104 may include one or more instructions stored on a computer-readable storage medium and executable by a processor of one or more computing devices (e.g., user client device 108, client device 600). When executed by one or more processors, the computer-executable instructions of the customized genotype imputation system 104 may cause the computing device to perform the bubble detection method described herein. Alternatively, the components of the customized genotype imputation system 104 may include hardware, such as a dedicated processing device that performs a specific function or a set of functions. Additionally or alternatively, the components of the customized genotype imputation system 104 may include a combination of computer-executable instructions and hardware.
[0177] In addition, the components of the custom genotype imputation system 104 that perform the functions described herein with respect to the custom genotype imputation system 104 may be implemented, for example, as part of a stand-alone application, as a module of an application, as a plug-in of an application, as one or more library functions that can be detected by other applications, and / or as a cloud computing model. Therefore, the components of the custom genotype imputation system 104 may be implemented as part of a stand-alone application on a personal computing device or a mobile device. Additionally or alternatively, the components of the custom genotype imputation system 104 may be implemented in any application that provides sequencing services, including but not limited to Illumina BaseSpace, Illumina DRAGEN or Illumina TruSight software, ExpansionHunter or Graph ExpansionHunter. "Illumina", "BaseSpace", "DRAGEN", "TruSight", "ExpansionHunter" and "Graph ExpansionHunter" are registered trademarks or trademarks of Illumina, Inc. in the United States and / or other countries.
[0178] As discussed in more detail below, embodiments of the present disclosure may include or utilize a special-purpose or general-purpose computer including computer hardware (such as, for example, one or more processors and system memory). Embodiments within the scope of the present disclosure also include physical and other computer-readable media for carrying or storing computer-executable instructions and / or data structures. Specifically, one or more of the processes described herein may be implemented at least in part as instructions embodied in a non-transitory computer-readable medium and executable by one or more computing devices (e.g., any of the media content access devices described herein). In general, a processor (e.g., a microprocessor) receives instructions from a non-transitory computer-readable medium (e.g., a memory, etc.) and executes those instructions, thereby performing one or more processes, including one or more of the processes described herein.
[0179] Computer readable media can be any available media that can be accessed by a general or special purpose computer system. A computer readable medium that stores computer executable instructions is a non-transitory computer readable storage medium (device). A computer readable medium that carries computer executable instructions is a transmission medium. Therefore, by way of example and not limitation, embodiments of the present disclosure may include at least two distinct types of computer readable media: a non-transitory computer readable storage medium (device) and a transmission medium.
[0180] Non-transitory computer-readable storage media (devices) include RAM, ROM, EEPROM, CD-ROM, solid-state drives (SSD) (e.g., RAM-based), flash memory, phase-change memory (PCM), other types of memory, other optical disk storage devices, magnetic disk storage devices or other magnetic storage devices, or any other media that can be used to store desired program code means in the form of computer-executable instructions or data structures and which can be accessed by a general or special purpose computer.
[0181] "Network" is defined as one or more data links that enable the transmission of electronic data between computer systems and / or modules and / or other electronic devices. When information is transferred or provided to a computer via a network or another communication connection (hardwired, wireless, or a combination of hardwired or wireless), the computer appropriately regards the connection as a transmission medium. The transmission medium may include a network and / or data link, which can be used to carry the desired program code means in the form of computer executable instructions or data structures, and which can be accessed by general or special computers. The above combinations should also be included in the scope of computer-readable media.
[0182] Furthermore, upon reaching various computer system components, program code means in the form of computer executable instructions or data structures may be automatically transferred from a transmission medium to a non-transitory computer readable storage medium (device) (or vice versa). For example, a computer executable instruction or data structure received over a network or data link may be buffered in RAM within a network interface module (e.g., NIC), and then ultimately transferred to the computer system RAM and / or to a less volatile computer storage medium (device) at the computer system. Thus, it should be understood that a non-transitory computer readable storage medium (device) may be included in a computer system component that also (or even primarily) utilizes a transmission medium.
[0183] Computer executable instructions include, for example, instructions and data that make a general-purpose computer, a special-purpose computer, or a special-purpose processing device perform certain functions or groups of functions when executed at a processor. In some embodiments, computer executable instructions are executed on a general-purpose computer to turn a general-purpose computer into a special-purpose computer that implements an element of the present disclosure. Computer executable instructions can be, for example, binary numbers, intermediate format instructions such as assembly language, or even source code. Although the subject matter has been described in a language specific to structural features and / or method actions, it should be understood that the subject matter defined in the appended claims is not necessarily limited to the described features or actions. On the contrary, the described features and actions are disclosed as exemplary forms of implementing the claims.
[0184] Those skilled in the art will appreciate that the present disclosure can be practiced in a network computing environment with many types of computer system configurations, including personal computers, desktop computers, portable computers, message processors, handheld devices, multiprocessor systems, microprocessor-based or programmable consumer electronics, network PCs, minicomputers, mainframe computers, mobile phones, PDAs, tablet computers, pagers, routers, switches, etc. The present disclosure can also be practiced in a distributed system environment, where both local and remote computer systems linked by a network (by a hardwired data link, a wireless data link, or a combination of hardwired and wireless data links) perform tasks. In a distributed system environment, program modules can be located in both local and remote memory storage devices.
[0185] Embodiments of the present disclosure may also be implemented in a cloud computing environment. In this specification, "cloud computing" is defined as a model for implementing on-demand network access to a shared pool of configurable computing resources. For example, cloud computing may be employed in the marketplace to provide ubiquitous and convenient on-demand access to a shared pool of configurable computing resources. A shared pool of configurable computing resources may be quickly provisioned via virtualization and released with low management effort or service provider interaction, and then scaled accordingly.
[0186] The cloud computing model may consist of various characteristics, such as, for example, on-demand self-service, broad network access, resource pooling, rapid elasticity, metered services, etc. The cloud computing model may also exhibit various service models, such as, for example, software as a service (SaaS), platform as a service (PaaS), and infrastructure as a service (IaaS). The cloud computing model may also be deployed using different deployment models, such as private cloud, community cloud, public cloud, hybrid cloud, etc. In this specification and in the claims, a "cloud computing environment" is an environment in which cloud computing is employed.
[0187] Fig.12 1 shows a block diagram of a computing device 1200 that can be configured to perform one or more of the above processes. It will be appreciated that one or more computing devices such as computing device 1200 can implement the custom genotype estimation system 104 and sequencing system 106. Fig.12 As shown, computing device 1200 may include a processor 1202, memory 1204, storage device 1206, I / O interface 1208, and communication interface 1210 that may be communicatively coupled via communication infrastructure 1212. In some embodiments, computing device 1200 may include Fig.12 Those shown may have fewer or more components. The following paragraphs describe in more detail Fig.12 Components of computing device 1200 are shown.
[0188] In one or more embodiments, the processor 1202 includes hardware for executing instructions such as those that constitute a computer program. As an example and not by way of limitation, in order to execute instructions for dynamically modifying a workflow, the processor 1202 may retrieve (or fetch) instructions from an internal register, an internal cache, a memory 1204, or a storage device 1206, and decode and execute them. The memory 1204 may be a volatile or non-volatile memory for storing data, metadata, and programs executed by the processor. The storage device 1206 includes a storage device for storing data or instructions for executing the methods described herein, such as a hard disk, a flash drive, or other digital storage device.
[0189] I / O interface 1208 allows a user to provide input to computing device 1200, receive output from the computing device and otherwise transfer data to the computing device and receive data from the computing device. I / O interface 1208 may include a combination of a mouse, a keypad or keyboard, a touch screen, a camera, an optical scanner, a network interface, a modem, other known I / O devices or such I / O interfaces. I / O interface 1208 may include one or more devices for presenting output to a user, including but not limited to a graphics engine, a display (e.g., a display screen), one or more output drivers (e.g., a display driver), one or more audio speakers and one or more audio drivers. In certain embodiments, I / O interface 1208 is configured to provide graphics data to the display for presentation to the user. Graphics data may represent one or more graphical user interfaces and / or may serve any other graphics content of a specific implementation.
[0190] The communication interface 1210 may include hardware, software, or both. In any case, the communication interface 1210 may provide one or more interfaces for communication (such as, for example, packet-based communication) between the computing device 1200 and one or more other computing devices or networks. As an example and not by way of limitation, the communication interface 1210 may include a network interface controller (NIC) or network adapter for communicating with an Ethernet or other wired-based network, or a wireless NIC (WNIC) or wireless adapter for communicating with a wireless network such as WI-FI.
[0191] Additionally, the communication interface 1210 can facilitate communication with various types of wired or wireless networks. The communication interface 1210 can also facilitate communication using various communication protocols. The communication infrastructure 1212 can also include hardware, software, or both that couple components of the computing device 1200 to each other. For example, the communication interface 1210 can use one or more networks and / or protocols to enable multiple computing devices connected through a particular infrastructure to communicate with each other to perform one or more aspects of the processes described herein. For illustration, a sequencing process can allow multiple devices (e.g., a client device, a sequencing device, and a server device) to exchange information such as sequencing data and error notifications.
[0192] In the foregoing description, the present disclosure has been described with reference to specific exemplary embodiments thereof. Various embodiments and aspects of the present disclosure are described with reference to the details discussed herein, and the accompanying drawings illustrate various embodiments. The above description and drawings are illustrative of the present disclosure and should not be construed as limiting the present disclosure. Many specific details are described to provide a thorough understanding of the various embodiments of the present disclosure.
[0193] The present disclosure can be embodied in other specific forms without departing from its spirit or essential characteristics. The embodiments described should be considered as being only exemplary and not restrictive in all respects. For example, the methods described herein can be performed with fewer or more steps / actions, or the steps / actions can be performed in different orders. Additionally, the steps / actions described herein can be repeated or performed in parallel with each other or in parallel with different examples of the same or similar steps / actions. Therefore, the scope of the application is indicated by the appended claims rather than the foregoing description. All changes within the equivalent meaning and scope of the claims will be included within their scope.
Claims
1. A computer-implemented method, comprising: generating a reference set comprising marker variant indications of marker variants at genomic coordinates of genomic samples corresponding to different haplotypes; adding at least one target variant position to the reference set that indicates the presence or absence of a target variant within the genomic sample; phasing the alleles of the genomic sample based on the marker variant to determine the presence or absence of the target variant in corresponding alleles present on the maternal haplotype and the paternal haplotype; and A target variant reference set is generated that includes target variant indications within the at least one target variant position of the phased alleles of the genomic sample.
2. The computer-implemented method of claim 1 , wherein: The at least one target variant position comprises a target variant position indicative of a biallelic target variant.
3. The computer-implemented method of claim 1 , wherein: The at least one target variant position comprises a plurality of target variant positions indicative of target variants of a multi-allelic target variant.
4. The computer-implemented method of claim 1 , wherein: Phasing the alleles of the genomic sample includes phasing heterozygous alleles of a subset of the genomic sample.
5. The computer-implemented method of claim 1 , wherein: The marker variants include single nucleotide polymorphisms (SNPs).
6. The computer-implemented method of claim 1 , wherein: Generating the reference set includes generating a phased reference set comprising the marker variant indices of marker variants phased according to the maternal haplotype and the paternal haplotype of the genomic sample.
7. The computer-implemented method of claim 1 , wherein: The genomic samples of different haplotypes include genomic samples of different haplotypes showing genetic diversity.
8. The computer-implemented method of claim 1 , wherein: The target variants include repeat sequence expansions.
9. The computer-implemented method of claim 1 , wherein: The target variants include deletions, insertions, duplications, inversions, translocations or copy number variations (CNVs) that are spread within a population.
10. The computer-implemented method of claim 1 , wherein: The target variants include variants of the replication factor C subunit 1 (RFC1) gene, the cytochrome P450 family 2 subfamily D member 6 (CYP2D6) gene, the cytochrome P450 family 2 subfamily B member 6 (CYP2B6) gene, the cytochrome P450 family 21 subfamily A member 2 (CYP21A2) gene, the survival of motor neuron 1 (SMN1) gene, the survival of motor neuron 2 (SMN2) gene, the glucocerebrosidase beta (GBA) gene, the blood group Rh (CE) (RHCE) gene, the lipoprotein (A) (LPA) gene, the fragile X mental retardation 1 (FMR1) gene, the hexosaminidase subunit alpha (HEXA) gene, the hemoglobin subunit alpha 1 (HBA1) gene, the hemoglobin subunit alpha 2 (HBA2) gene or the hemoglobin subunit beta (HBB) gene.
11. The computer-implemented method of claim 1 , wherein: The target variant satisfies one or more of a threshold carrier rate, a threshold linkage disequilibrium (LD) with respect to a particular marker variant, or a threshold mutation rate.
12. A system comprising: at least one processor; and A non-transitory computer-readable medium comprising instructions that, when executed by the at least one processor, cause the system to: identifying nucleotide reads corresponding to the target genomic sample; accessing a target variant reference set comprising an indication of a target variant within at least one target variant position of phased alleles of genomic samples of different haplotypes; and A genotype call of a target variant within the target genomic sample is inferred based on a comparison of a target variant reference set to the nucleotide reads corresponding to the target genomic sample.
13. The system according to claim 12, wherein: The target variant indication indicates the presence or absence of the target variant in the at least one target variant position of the phased alleles in the genomic sample.
14. The system of claim 12, further comprising instructions that, when executed by the at least one processor, cause the system to: determining phased alleles for the target genomic sample based on the comparison of the target variant reference set to the nucleotide reads corresponding to the target genomic sample; and The genotype call is imputed by imputing a phased genotype call of the target variant within the target genomic sample based on the phased alleles of the target genomic sample.
15. The system of claim 12, further comprising instructions that, when executed by the at least one processor, cause the system to infer the genotype call of the target variant by generating a prediction of whether the target genomic sample includes the target variant.
16. The system of claim 15, further comprising instructions that, when executed by the at least one processor, cause the system to generate the prediction by predicting whether the target genomic sample includes a pathogenic variant at an allele present on a maternal haplotype or a paternal haplotype.
17. The system of claim 12, further comprising instructions that, when executed by the at least one processor, cause the system to deduce the genotype call by: identifying one or more single nucleotide polymorphisms (SNPs) within the nucleotide reads corresponding to the target genomic sample as one or more marker variants within the target variant reference set for the target variant; and The genotype call is determined based on the one or more SNPs within the nucleotide reads.
18. The system of claim 12, further comprising instructions that, when executed by the at least one processor, cause the system to infer the genotype call of the target variant by inferring the genotype call of a repetitive sequence expansion.
19. The system of claim 12, further comprising instructions that, when executed by the at least one processor, cause the system to utilize a genotype imputation model to impute the genotype calls.
20. A non-transitory computer-readable medium storing instructions that, when executed by at least one processor, cause a computing device to: identifying nucleotide reads corresponding to the target genomic sample; accessing a target variant reference set comprising an indication of a target variant within at least one target variant position of a phased allele of a genomic sample; and A genotype call of a target variant within the target genomic sample is inferred based on a comparison of a target variant reference set to the nucleotide reads corresponding to the target genomic sample.
21. The non-transitory computer readable medium of claim 20, wherein: The target variant indication indicates the presence or absence of the target variant in the at least one target variant position of the phased allele in a genomic sample.
22. The non-transitory computer-readable medium of claim 20, further comprising instructions that, when executed by the at least one processor, cause the computing device to: determining phased alleles for the target genomic sample based on the comparison of the target variant reference set to the nucleotide reads corresponding to the target genomic sample; and The genotype call is imputed by imputing a phased genotype call of the target variant within the target genomic sample based on the phased alleles of the target genomic sample.
23. The non-transitory computer-readable medium of claim 20, further comprising instructions that, when executed by the at least one processor, cause the computing device to infer the genotype call of the target variant by generating a prediction of whether the target genomic sample includes the target variant.
24. The non-transitory computer-readable medium of claim 20, further comprising instructions that, when executed by the at least one processor, cause the computing device to calculate the number of genes encoding the replication factor C subunit 1 (RFC1) gene, the cytochrome P450 family 2 subfamily D member 6 (CYP2D6) gene, the cytochrome P450 family 2 subfamily B member 6 (CYP2B6) gene, the cytochrome P450 family 21 subfamily A member 2 (CYP21A2) gene, the motor neuron The genotype detection of the target variant is inferred from the genotype detection of the survival 1 (SMN1) gene, the survival motor neuron 2 (SMN2) gene, the glucocerebrosidase beta (GBA) gene, the blood group Rh (CE) (RHCE) gene, the lipoprotein (A) (LPA) gene, the fragile X mental retardation 1 (FMR1) gene, the hexosaminidase subunit alpha (HEXA) gene, the hemoglobin subunit alpha 1 (HBA1) gene, the hemoglobin subunit alpha 2 (HBA2) gene or the hemoglobin subunit beta (HBB) gene.
25. The non-transitory computer readable medium of claim 20, wherein: The target variant reference set includes marker variant indications for marker variants within the target genomic region of the target variant and additional marker variant indications excluding additional marker variants outside the target genomic region.
